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Abstract 
Pertussis, more commonly known as whooping cough, is one of the most common 
vaccine-preventable infections reported in Australia. In the last decade, pertussis 
incidence has increased in Australia and overseas, with large sustained epidemics 
occurring most notably in developed countries. Australia had a pertussis epidemic 
between 2009 and 2012, which peaked during 2011 with 38,602 notified cases. The role of 
improved diagnostic methods, particularly the use of polymerase chain reaction (PCR) 
testing, has been hypothesised to have led to improved case ascertainment and superior 
detection of disease activity. This Thesis is comprised of five distinct studies contributing to 
the investigation of this hypothesis.  
In Australia, the incidence of pertussis is predominantly monitored using notification data, 
with the case definition for notifications heavily reliant on laboratory confirmation. By 
analysing pertussis notifications between 1991 and 2013 by diagnostic test method, I was 
able to demonstrate that PCR quickly replaced all other laboratory methods for pertussis 
diagnosis from 2005 onwards, with the exception of persisting serology use in a proportion 
of adolescents and adults. In addition, a change in the age distribution of notifications was 
observed over time, with increasing pertussis incidence among older children and 
adolescents.  
As notification data can be biased by changes in testing practices, awareness, and 
definitions, my next study investigated pertussis testing trends in the general practice (GP, 
primary care) setting between 2000 and 2011 using data from the Bettering the Evaluation 
And Care of Health (BEACH) program. Among a stable set of GP encounters for 
respiratory illness, it was observed that the likelihood of individuals being tested for 
pertussis in 2010-2011 was seven times higher compared to ten years earlier. These 
findings, at least in part, suggest that notifications have been amplified due to increased 
testing.  
To gather more information about the contribution of increased testing to the pertussis 
epidemic, the incidence of severe pertussis cases admitted to intensive care units (ICUs) 
was reviewed, as the ICU setting is less likely to be biased by changes in diagnostic 
testing. Data on Australian paediatric pertussis-related ICU admissions between 1997 and 
2013 were obtained from the Australian and New Zealand Paediatric Intensive Care 
(ANZPIC) Registry. I found that there had been an increase in pertussis-related ICU 
 
 
iii 
admissions during the epidemic period (2009-2012), likely indicating a true increase in 
pertussis activity in Australia. Focussing then on a subset of the ANZPIC Registry data, 
the diagnostic testing of pertussis-related paediatric ICU admissions in Queensland was 
reviewed. This analysis identified that PCR largely replaced other diagnostic methods over 
time and became the predominant diagnostic test, mirroring what had previously been 
observed among national pertussis notifications. 
With my final study, I investigated the impact of diagnostic testing changes on the 
understanding of pertussis epidemiology, focussing specifically on pertussis seasonality, 
which although a previously accepted phenomenon, can no longer be observed in 
notification data. By calculating the proportion of positive pertussis tests conducted, this 
study demonstrated that pertussis remains a seasonal illness, with peaks in summer each 
year, highlighting the need to monitor underlying testing patterns to truly understand 
disease epidemiology.  
When considered in combination, the findings of my Thesis support the hypothesis that 
while there was a real increase in pertussis activity in Australia between 2009 and 2012, 
the increased likelihood of testing and shift to more sensitive PCR-based diagnosis are 
likely to have magnified the recorded incidence of pertussis. The practical effect of these 
findings together with rapidly waning immunity following the introduction of acellular 
vaccines, and the removal of the vaccine booster dose for 18 month olds in 2003 in 
Australia, all contributed to the recent resurgence of pertussis. 
This Thesis makes an important and original contribution to understanding the recent 
resurgence of pertussis in Australia and overseas by addressing gaps in knowledge about 
changes in diagnostic testing. Although a true increase in pertussis incidence occurred in 
Australia, increasing PCR diagnosis allowed better case detection across all age groups 
and healthcare settings. Greater understanding of pertussis epidemiology as a result of 
PCR diagnosis should ultimately improve pertussis immunisation and control programs, 
through better identification of at-risk groups.  
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Thesis Introduction, Aims and Structure 
Introduction to the Thesis Topic 
Pertussis, more commonly known as whooping cough, is one of the most common 
vaccine-preventable infections reported in Australia.1 For some cases, initial symptoms 
can be mild and similar to that of the common cold, however this phase of illness is 
typically followed by a period of protracted non-specific coughing illness that can cause 
sleep disturbances and affect other daily activities.2,3 For a subset of cases, particularly 
those younger than six months of age, the clinical illness can be severe and require 
hospitalisation. Severe cases can experience a wide range of clinical complications and 
occasionally result in death.2,3  
In Australia pertussis vaccines have been widely used since 19424 and were included on 
the Australian National Immunisation Schedule when it was first established in 1975. At 
that time pertussis immunisation used whole-cell vaccine and consisted of a three-dose 
primary series with doses at three, four, and five months, followed by a single booster 
dose at 15-18 months.4 Since then there have been variations in the timing and number of 
pertussis vaccine doses, as well as changes in the vaccine formulations used.4 In 2016, 
the National Immunisation Schedule uses only acellular pertussis vaccines and includes a 
three-dose primary series, with doses at six weeks, four months, and six months, followed 
by three booster doses at 18 months, four years, and 15 years.4 Additional doses are also 
recommended for some adults, including pregnant women, healthcare workers, and the 
elderly (aged 65 or older).4  
Despite well-established immunisation programs, pertussis incidence has increased in 
Australia and overseas over the last decade, with large sustained epidemics occurring 
most notably in developed countries.5-7 Australia had a pertussis epidemic between 2009 
and 2012, which peaked during 2011 with 38,602 notified cases.1 The resurgence of 
pertussis prompted concerns about the effectiveness of pertussis control strategies and 
immunisation programs.8  
It has been hypothesised that the resurgence of pertussis over the last decade could be 
attributed to numerous factors, including: improved diagnostic methods and case 
detection, declining vaccine coverage, changes in vaccination schedules, changes in 
vaccine formulations (whole cell to acellular), waning of vaccine-derived immunity, or 
Bordetella pertussis strain variation.6-10 
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Thesis Research Aims  
The key aims of this Thesis are: 
1. To describe the epidemiology of pertussis in Australia, using routinely collected data; 
2. To describe changes in the use of diagnostic methods to test for and/or diagnose 
pertussis in different healthcare settings, using routinely collected data; and 
3. To infer (from 1 and 2) the impact that changes in diagnostic testing have made on 
the understanding of pertussis epidemiology in Australia.  
Thesis Structure  
This Thesis has eight chapters, of which five are individual research projects. Chapter 1 
provides a literature review on Bordetella pertussis, including the clinical illness, 
epidemiology, vaccines and immunisation, diagnosis, public health significance, and gaps 
in current knowledge. The subsequent chapters (2 to 6) were individual research studies 
focused on specific research questions. Each of these chapters consists of a published or 
submitted manuscript.  
In Australia, the incidence of pertussis is predominantly monitored using notification data. 
In Chapter 2, by analysing pertussis notifications I was able to show that PCR quickly 
replaced all other laboratory methods for pertussis diagnosis from 2005 onwards, with the 
exception of serology among a proportion of adolescents and adults. In addition, a change 
in the age distribution of notifications was observed over time, with increasing incidence 
among children and adolescents. As notification data can be biased by changes in testing 
practices, awareness, and definitions,6,11,12 in Chapter 3, I investigated changes in 
pertussis testing trends over time in the general practice (GP) setting. In this chapter, I 
show that among individuals presenting to Australian GPs with respiratory illness, the odds 
of being tested for pertussis in 2010-2011 were seven times higher than ten years earlier. 
These findings, at least in part, explain an increase in notifications as an artefact of 
increased testing.  
I hypothesised that the incidence of severe pertussis cases, particularly those admitted to 
intensive care units (ICUs), would be less biased by changes in diagnostic testing. In 
Chapter 4, I reviewed the epidemiology of Australian paediatric pertussis-related ICU 
admissions and observed an increase in cases during the recent epidemic period 
(2009-2012), indicating that pertussis activity had increased and the epidemic was not just 
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due to increased testing. I subsequently reviewed the diagnostic testing of pertussis-
related paediatric ICU admissions in Queensland (Chapter 5), and found that, like among 
notifications, there was a clear shift towards PCR testing.  
In Chapter 6, I investigated the impact of diagnostic testing changes on the understanding 
of pertussis epidemiology. The focus of this chapter was specifically on pertussis 
seasonality, which was once an accepted phenomenon but is no longer observed in 
notification data. By calculating the proportion of positive pertussis tests conducted, I was 
able to show that pertussis remains a seasonal illness with peaks in summer each year, 
thereby highlighting the need to understand underlying testing patterns.  
Finally, in Chapter 7 the previous chapters are summarised and the Thesis is discussed as 
a whole, including implications of the research findings and overall conclusions. 
The focus of this Thesis is on pertussis, however two studies are included that have 
incorporated both pertussis and influenza (Chapters 3 and 5). Some similarities exist for 
both pertussis and influenza in terms of changing diagnostic methods, and as such, it was 
opportunistic and appropriate to incorporate both diseases in these two studies. In order to 
maintain emphasis on the Thesis research aims, influenza has not been included in the 
introduction (Chapter 1) or discussion (Chapter 7). 
CHAPTER 1 
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Chapter 1 – Literature Review  
Bordetella pertussis 
Pertussis, or whooping cough, is a respiratory illness that can affect individuals of all 
ages.3 It is almost always caused by the bacterium Bordetella pertussis, but in a subset of 
cases it can be caused by other Bordetella species, such as B. parapertussis and 
B. holmesii.3,13-20 Bordetella species are all gram negative bacilli that express various 
virulence factors on their outer surface, including filamentous hemagglutinin (FHA), 
pertactin (PRN), and fimbrial antigens of agglutinogens (FIM).2,3,10,21,22 Unlike the other 
Bordetella species, only B. pertussis produces pertussis toxin (PT).2,3,10,21,22 The outer 
surface virulence factors and pertussis toxin are all involved in assisting the bacteria to 
colonise the respiratory tract and establish infection, and as such, acellular pertussis 
vaccines are made up of combinations of these components.2,21 
Pertussis has an average incubation period of between seven to 10 days (range 6-20 
days) before the onset of symptoms.2,21,23 Typically, early infection is characterised by the 
catarrhal stage which consists of one to two weeks of coryzal symptoms. This is typically 
followed by the paroxysmal stage which usually involves uncontrollable fits of forceful 
coughing that can be followed by a characteristic high-pitched "whoop" sound as the 
patient struggles to breathe in, and post-tussive vomiting.3,21,23  
For many individuals, including those with prior natural or vaccine-derived immunity and 
infants younger than six months of age, the characteristic symptoms (inspiratory whoop 
and post-tussive vomiting) may not be present. Instead, initial symptoms can be mild and 
similar to that of the common cold followed by a protracted non-specific coughing 
illness.2,3,24-26 In some cases, although the illness itself may be mild, prolonged coughing 
can cause sleep disturbances and affect other daily activities.3,23 Sub-clinical infections 
may also occur.3 
Young children, especially infants younger than six months of age, are at highest risk of 
severe outcomes, including death, in part due to their immature immune and 
cardiorespiratory systems.27 Clinical complications of pertussis can include, but are not 
limited to, apnoea in young infants, bronchoalveolar pneumonia in individuals of any age, 
seizures, encephalopathy, hypoxic brain injuries, and respiratory distress syndrome.2,3,21,28 
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Individuals are most infectious during the initial catarrhal stage and early coughing stage, 
with person to person spread through droplet transmission.29 It has been estimated that 
pertussis has a basic reproductive number (R0) between 15-17, meaning that a single 
case can infect 15-17 susceptible individuals.3,30 The communicability gradually declines 
over time and cases are considered non-infectious three weeks after the onset of 
cough.2,21,23 Pertussis can be treated using antibiotics, particularly macrolides.2,3 
Antibiotics are most beneficial in reducing the severity and duration of illness if started 
during the early coryzal stage or within three weeks of cough onset.2,3 Early 
commencement of antibiotics can also reduce the period of communicability.10,23   
Epidemiology 
Global 
Prior to the widespread use of whole cell vaccines in the early to mid-20th century, 
B. pertussis was responsible for significant morbidity and mortality worldwide. Annual 
incidence estimates during this period ranged from 153 and 157 cases per 100,000 
population per year in Canada and the United States, respectively, to 650 per 100,000 
population per year in Romania.30-33 In Japan it was reported that over 17,000 pertussis-
related deaths occurred during 1947.31,32 During this period, diagnosis would have been 
based predominantly on clinical syndrome rather than laboratory diagnostic methods, and 
both cases and deaths may have been under-reported. In the pre-vaccination era, 
approximately 10% of pertussis cases occurred in infants younger than 12 months old, and 
95% occurred in children younger than 10 years old.31 It was common for pertussis 
epidemics to occur approximately every three years in a cyclical pattern.31  
Following the introduction of routine vaccination, substantial reductions were observed in 
the incidence of B. pertussis infections. Although many countries reported incidence rates 
declining to 1-20 per 100,000 population per year,5,30-37 this was still likely to be under-
reporting the true disease burden.38 The overall morbidity and mortality associated with 
B. pertussis infection also decreased, but hospitalisations and deaths continued to occur, 
primarily in infants younger than six months of age.31,39  
Widespread vaccination led to a shift in the observed age, with approximately 50% of 
pertussis cases being reported in infants younger than 12 months of age and a growing 
proportion of pertussis cases being reported in adolescents and adults.31 The incidence of 
pertussis in adolescents and adults has been increasing, especially in countries where 
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vaccination coverage in young children is high.31,35,38,40-47 Even following widespread 
vaccination, pertussis epidemics continue to occur approximately every three to five years 
in a cyclical pattern, indicating that B. pertussis remained endemic within vaccinated 
populations.31,48,49  
Although significant declines in pertussis incidence followed widespread vaccination, many 
countries, including the United States, began to report increases in incidence from 
approximately 1990 onwards, which reached epidemic proportions in some countries 
between 2005 and 2010.5-7,37,48,50  
In the last decade, epidemics have been reported worldwide, most notably in developed 
countries with established surveillance systems.5,6,8,9,30,51-53 In the United Kingdom, 
pertussis is currently one of the most commonly reported vaccine preventable diseases, 
despite maintaining childhood vaccination coverage above 90% over the last 15 years.54 In 
Germany during 2008, reported pertussis incidence was similar to that observed during the 
pre-vaccination era, at a rate of approximately 60 cases per 100,000 population per year.30 
Epidemics have also been reported across the United States, although the timing and 
severity varied by region.51-53,55 Resurgence in Canada has also been reported, however it 
has been suggested that this is partly due to increasing diagnostic testing.11 
Globally, the World Health Organization estimated that during 2008, 16 million cases of 
pertussis occurred, and 195,000 deaths were reported in children younger than five years 
of age.56,57 Approximately 95% of the global burden of pertussis occurs in developing 
countries.56,57 Regions with high vaccination coverage have observed a shift in the age 
distribution of cases into older age groups, prompting concern that adolescents and adults 
may be serving as reservoirs for B. pertussis.7,28,58,59  
Australia 
In Australia, during the pre-vaccination era (before 1950), pertussis epidemics were 
associated with extremely high incidence rates as well as high rates of pertussis-related 
deaths (>4 deaths per 100,000 population per year).23 After whole cell vaccines became 
widely used in the 1950s, pertussis rates began to decline. The annual number of 
pertussis cases nationally during the 1980s ranged from 100 to 800 cases per year, but 
increased to between 1,000 and 10,000 per year during the 1990s. During these periods, 
adults had higher rates of pertussis compared to children, although hospitalisations and 
deaths occurred predominantly in very young infants, especially Aboriginal and Torres 
Strait Islander infants.60,61 
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Although pertussis vaccination rates in Australian children and adolescents have remained 
high since approximately 2000,62 notifications began to increase in 2008.63 An epidemic 
period (2009-2012) occurred across all eight States and Territories.63 During this epidemic 
period, pertussis was one of the two most commonly notified vaccine preventable diseases 
in Australia (influenza being the other), and notifications peaked in 2011 with 38,602 
cases.1,63-65 Notification rates were highest among children younger than 15 years of age, 
peaking in 2011 among the five to nine year old age group at 552 cases per 100,000 
population per year.8,65 The highest rates of hospitalisations and deaths continued to occur 
in infants younger than six months of age.8 By 2013, pertussis activity had decreased 
across all States and Territories to pre-epidemic levels.1 
Vaccines and Immunisation 
Vaccines 
Once methods to isolate and propagate B. pertussis on culture media were developed at 
the beginning of the 20th century, vaccine development began.2 Early pertussis vaccines 
were a suspension of killed bacterial cells and therefore referred to as ‘whole cell’ 
vaccines.2,4,66 In Australia, the first whole cell pertussis vaccine was licensed in 1920, six 
years after the United States (1914).2,4 To begin with, there was no standardisation of 
production methods or vaccine contents. It was not until the 1930s that efforts were made 
to improve whole cell vaccines by changing how the bacteria were killed, standardising 
culture media and which bacteria to use, and ensuring the presence of an adequate 
number of killed bacterial cells in the vaccine.2 Clinical trials were able to demonstrate the 
efficacy of early whole cell vaccines, and once mouse models were available, there was 
further evidence of efficacy after vaccine potency and immune challenge studies were 
conducted.2 Although there was evidence that whole cell vaccines were efficacious, 
differences in manufacturing methods were found to affect vaccine efficacy and antibody 
levels.2,67,68 Whole cell pertussis vaccines were very immunogenic but they were also 
highly reactogenic, commonly causing minor local reactions and occasionally causing 
more severe systemic reactions, such as acute encephalopathy, febrile seizures, 
hypotonic-hyporesponsive episodes, prolonged or inconsolable crying, and 
anaphylaxis.2,4,66,68 Over time increasing reports of adverse events led to declining public 
acceptance of whole cell vaccines and a demand for less reactogenic pertussis 
vaccines.2,66,67 
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By the 1970s there was better understanding of the structure of B. pertussis, including 
specific components and their role in disease, which facilitated the production of acellular 
or purified component vaccines.2,66 Research into these vaccines began in Japan, and 
following the successful production and use of acellular vaccines in the Japanese setting, 
interest in acellular vaccines spread internationally.69-72 Acellular vaccines were found to 
be much less reactogenic, while providing equivalent or improved efficacy, and therefore 
were considered much safer and more acceptable than whole cell vaccines.67,73-75 
Acellular pertussis vaccines started replacing whole cell vaccines in Australia, Canada, the 
United States, and some Asian and European countries from the mid-1990s, however 
many countries across Europe, Asia, Africa, the Middle East, and South America continue 
to use whole cell vaccines to this day.2,57,66 
Unlike whole cell vaccines, acellular vaccines are made up of a combination of outer 
surface virulence factors and pertussis toxin, most commonly as three component or five 
component formulations.2,21 Three component acellular vaccines contain: filamentous 
hemagglutinin (FHA), pertactin (PRN), and pertussis toxin (PT); with the five component 
vaccines also including two fimbrial antigens of agglutinogens (FIM).2,3,10,21,22  
Acellular pertussis vaccines are generally combined with components of other pathogens, 
most commonly diphtheria and tetanus, in a single vaccine. These are referred to as DTPa 
and dTpa in Australia, or TDaP and Tdap in the United States and elsewhere. DTPa/TDaP 
is used for children younger than ten years of age and dTpa/Tdap is used for adolescents 
(≥10 years) and adults.10,21 Across manufacturers there are differences in vaccine 
production methods, the combination and included quantity of the pertussis, diphtheria, 
and tetanus components, and there is varied use of adjuvants, diluents, and 
preservatives.2  
As the number of recommended childhood vaccinations at each age milestone has 
increased, vaccine manufacturers have developed products which combine multiple 
vaccinations into a single injection in an effort to reduce discomfort and increase 
acceptability and compliance. For example, pertussis vaccines are now commonly 
delivered with one or more of hepatitis B (hepB), Haemophilis influenzae type B (Hib), 
and/or inactivated poliomyelitis vaccine (IPV), into quadravalent (DTPa-IPV), pentavalent 
(DTPa-IPV-Hib), or hexavalent (DTPa-IPV-Hib-hepB) combination vaccines.2,4,21,76 
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Vaccine efficacy and effectiveness  
To determine the protective effect that vaccines have against disease, their efficacy can be 
assessed in a clinical trial setting (usually against a placebo or comparison vaccine), or 
their effectiveness can be assessed in the ‘real world’ using retrospective cohort or case-
control study designs.  
A Cochrane Review found the efficacy of acellular vaccines with three or more 
components varied between 84-85% for preventing ‘typical’ pertussis, and 71-78% for 
preventing mild pertussis. One and two component acellular vaccines had lower efficacy, 
between 59-78% for ‘typical’ illness and 41-54% for mild illness.77 In comparison, four 
doses of whole cell vaccine were found to be 70-90% effective in preventing serious 
illness.77 Overall, the Cochrane Review concluded that acellular vaccines (with 
≥3 components) were more effective than low-efficacy whole cell vaccines, but may be 
less effective than the highest-efficacy whole cell vaccines.67 It is however, difficult to 
compare vaccine efficacy estimates between studies due to variation in the vaccines 
produced by different manufacturers, as well as because of differences in study designs, 
immunisation schedules, case definitions, case ascertainment, outcome being investigated 
(and how it is measured), and period of follow up.7,67,78,79  
Estimates of vaccine effectiveness (VE) also vary considerably between studies, and are 
difficult to compare, due to the same issues as vaccine efficacy studies.67,79 The majority 
of VE studies have focussed on the effectiveness of vaccines against notifications, which 
often report the whole spectrum of illness from mild to severe infections. For example, 
Witt et al. (2012) calculated VE estimates against PCR-confirmed pertussis for fully 
vaccinated children (with the number of doses varying by age group) presenting to a large 
medical centre using the screening method. The VE was found to be 41% for children 
aged two to seven years (four or five vaccine doses), 24% for children aged eight to twelve 
years (five or six vaccine doses), and 79% for adolescents (aged 13-18 years; six vaccine 
doses).80 In Australia, following an adolescent acellular vaccine immunisation catch up 
program, VE against laboratory-confirmed notifications among adolescents (aged 
12-19 years), calculated using the screening method, was estimated to be 84.3% for 
PCR-confirmed cases and 88.8% for serology-confirmed cases.81 Another Australian 
study, also using the screening method to investigate VE of acellular vaccines against 
laboratory-confirmed notifications, found VE point estimates to be between 78.2% to 
91.7% for children aged one to less than four years (three vaccine doses), between 64.7% 
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and 87.4% for children aged five to less than eight years (four doses), and between 43.3% 
and 78.1% for children aged eight to less than 12 years (five doses).82 
Infant pertussis vaccination has been demonstrated to reduce the rate of hospitalisation, 
even after a single dose,83-86 however to date, few studies have specifically assessed the 
effectiveness of acellular pertussis vaccines against severe infection.82,85,87,88 
Rendi-Wagner et al. (2006), using the screening method, estimated that the VE for 
preventing hospitalisation in children aged younger than 15 years, after 3 doses, was 79% 
for whole cell vaccine and 92% for acellular vaccine.87 In another study using the 
screening method, Juretzko et al. (2002) estimated that the age-adjusted VE for 
preventing hospitalisation among children aged two to 18 months was 68.0% after one 
dose, 91.8% after two doses, 99.8% after three doses, and 98.6% after four doses.88 In an 
Australian study, also using the screening method, Sheridan et al. (2014) estimated that 
the VE against pertussis hospitalisation, after three vaccine doses, was between 85.6% 
and 87.1% for children aged one to less than four years.82 Another Australian study, using 
case-control methodology, estimated that VE against ICD-10 coded pertussis 
hospitalisation, after three doses of vaccine, was 83.5% in infants six to less than 
12 months of age.89  
A VE study’s measured outcome, whether notifications or hospitalisations, can be a source 
of bias within the study itself and can also make it difficult to compare VE studies. 
Notifications can be affected by changes over time or by region in case definitions, case 
ascertainment, laboratory diagnostic methods, as well as public and clinician awareness. 
Similarly, hospitalisations can be affected by changes over time or by region in clinician 
awareness, laboratory diagnostic methods, hospitalisation indications, as well as 
diagnosis/discharge coding.67,79,82,87-89 
Duration of immunity 
Neither infection nor immunisation produce life-long immunity to pertussis, with protective 
immunity waning over time and leading to reinfections throughout life. The duration of 
protection following natural immunity is thought to wane in the four to 20 years after 
infection.90 Vaccine-derived immunity following immunisation with whole cell vaccines was 
estimated to wane after four to 12 years, and early estimates predicted that the duration of 
immunity following acellular vaccines would be similar.90 However, more recent estimates 
indicate that acellular vaccine-derived immunity rapidly wanes with progressive decreases 
in VE each year following vaccination.55,80,89,91-94 An Australian case-control study 
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estimated VE against hospitalisation to be 83.5% among infants six to less than 12 months 
of age, after three doses of acellular vaccine.89 In the subsequent age cohorts, VE 
estimates declined to 70.7% among children aged between two and three years, and to 
59.2% among children aged between three and four years.89 
Duration of vaccine-derived immunity has also been found to be different among children 
who had a combination of both whole cell and acellular vaccines administered, with the 
number of whole cell/acellular vaccine doses and initial priming dose playing an important 
role.95 Sheridan et al. (2012) found that infants who received whole cell vaccine for all 
primary series doses and, to a lesser extent those that received a whole cell vaccine for 
the first dose, had lowered risk of subsequent pertussis infection, compared to infants that 
received all acellular doses or an acellular first dose.95 
Immunisation strategies and coverage 
Pertussis vaccines have been widely used in Australia since 1942.4 When the Australian 
National Immunisation Schedule was first established in 1975, pertussis immunisation 
used whole cell vaccine and consisted of a three-dose primary series, with doses at three, 
four, and five months, followed by a booster at 15-18 months. Since then the timing, 
number of doses, and vaccines used have varied (Figure 1).4 Following widespread 
immunisation of young infants, there was an observed shift in the age profile of pertussis 
to older children and adolescents in Australia and overseas.96-99 As a result, immunisation 
recommendations were expanded to include booster doses for older children and 
adolescents, in an effort to reduce the incidence of pertussis in these age groups as well 
as lower the risk of pertussis transmission to young infants.37,99-102 In 1997, scheduled 
booster doses of combination (diphtheria, tetanus, pertussis) whole cell vaccines were 
replaced with combination acellular vaccines, and from 1999, combination acellular 
vaccines were used for all scheduled primary series and booster doses.4,21 
The primary aim of pertussis immunisation is to protect young infants against severe 
illness.21 The current Australian National Immunisation Schedule, last updated in June 
2015, consists of a three-dose primary series of pertussis-containing vaccine, at six to 
eight weeks, four months, and six months of age, as well as three booster doses, at 
18 months, four years, and 15 years of age.4,21 In addition, pertussis immunisation is 
currently also recommended (but not nationally funded) for healthcare and childcare 
workers, pregnant women, household contacts and carers of infants younger than six 
months of age, the elderly (aged 65 years and older), adults aged 50 years and older who 
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have not had a dT booster in the previous 10 years, as well as any adult who wishes to 
reduce the likelihood of B. pertussis infection.21   
Figure 1: Timeline of Australia’s pertussis immunisation schedule 
 
Source: Adapted from National Centre for Immunisation Research and Surveillance web page “Significant 
events in diphtheria, tetanus and pertussis vaccination practice in Australia” 2015 4 
 
Despite the well-established pertussis immunisation programs in Australia and overseas, 
infants younger than six months of age continue to be at highest risk of severe 
outcomes.10,86,89,103-106 In the future, new pertussis vaccines may be able to provide earlier 
and longer lasting protection by utilising live attenuated B. pertussis strains, novel soluble 
or micro-particle vaccine formulations, improved adjuvants, or mucosal delivery,107-109 
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however as these novel vaccines may still be many years away, other strategies need to 
be considered to protect young infants.10,61,103,105 
The “cocoon” strategy, which attempts to protect newborn infants by immunising their 
close contacts, such as parents and other caregivers, has been proposed as a possible 
solution.4,10,61,110-114 Parents and siblings have been found to be the most likely sources of 
transmission to newborn infants,59,61,115-119 although healthcare workers are also a 
common source of infection.120-123 In Australia during 2009, in response to the increasing 
incidence of pertussis, cocoon vaccination programs were funded by State and Territory 
governments,4 even though evidence of the effectiveness of the cocoon strategy was 
limited. The eligibility criteria, implementation, and timing of these state-based programs 
varied by jurisdiction.4 As pertussis rates began to decline in 2012, State and Territory 
governments began to withdraw funding for their programs.4  
Another strategy to protect newborn infants is maternal vaccination. The concept of 
maternal vaccination against pertussis is not a novel one, with research into this area 
having been conducted during the late 1930s and 1940s. At that time, maternal 
vaccination (with whole cell vaccine) was found to be effective in providing immunity to 
both the mother and infant at birth, but the concept was abandoned as it was found that 
high levels of maternal antibodies in infants led to the suppression of their immune 
responses to subsequent vaccination with DTPw vaccine.2,61,124,125 Later research found 
that the inhibitory effect is dependent on the ratio of maternal antibodies and the antigen 
dose given to the infant, so interference was negligible when infants were immunised 
according to the routine schedule using acellular vaccines.125-128 In response to increases 
in pertussis activity globally, where young infants, particularly younger than four months of 
age continued to be at risk, interest in maternal vaccination returned. Public Health 
England commenced a maternal pertussis vaccination program in 2012, with a large 
evaluation component involving a case-control study and other observational studies. This 
program was found to be safe, with no evidence of any adverse events relating to 
pregnancy outcomes, and VE was estimated as 91% against confirmed pertussis in infants 
younger than 2 months of age.129-132 In addition to the program in the United Kingdom, 
several other studies (based in the United States and Belgium), have also demonstrated 
the safety, and efficacy/effectiveness of maternal pertussis vaccination.133-137 In 2011, the 
United States Advisory Committee on Immunization Practice recommended pertussis 
vaccination for unimmunised pregnant women, and in 2012, expanded this 
recommendation to include booster doses of pertussis vaccine during every 
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pregnancy.138,139 In Australia, a pertussis booster for pregnant women during the third 
trimester of each pregnancy was recommended by the Australian Technical Advisory 
Group on Immunisation in March 2015, and all States/Territories subsequently 
commenced locally-funded programs.4,21 Evaluations of the impact of maternal vaccination 
on pertussis epidemiology will be an important area of research over the coming years. 
Due to the resurgence of pertussis, interest also returned to neonatal pertussis vaccination 
as a possible strategy to better protect young infants.10 Studies were initially conducted 
during the 1950s, focussing on the efficacy of neonatal whole cell pertussis vaccination, 
but the strategy was abandoned when findings indicated that although protective immunity 
was reached early in life, overall antibody levels were lower following receipt of all 
scheduled doses.61,140 More recently, various studies investigating the efficacy of a birth 
dose of acellular pertussis vaccine have had somewhat conflicting results, although the 
studies did differ in vaccine formulation, schedule, and follow up timing.10,61,83,141-143 While 
neonatal pertussis vaccination may be an option in the future, further research is needed 
to establish the safety and efficacy of this approach, with early findings suggesting that 
antibody interference may be a significant obstacle to overcome.10,61,107,128,140 
Globally, all pertussis immunisation strategies are consistent in their aim to protect young 
infants who are at highest risk. The current Australian National Immunisation Schedule 
and recommendations are largely comparable to schedules/recommendations overseas, 
although there is variation worldwide in regards to the vaccines used, recommended 
timing, and total number of doses.2,3,10,48,57,144-147 
Vaccine coverage 
The Australian Childhood Immunisation Register (ACIR), established on 01 January 1996, 
provides a nearly complete population register, recording all scheduled vaccine doses 
provided to enrolled children under the age of seven years. Enrolment on the ACIR is on 
an opt-out basis and captures approximately 99% of children younger than 12 months of 
age registered with Medicare. Children not enrolled with Medicare can be added to the 
ACIR, however coverage estimates are calculated using the number of children enrolled 
on the register as the denominator, rather than total children in the population.62,148  
In 2012, 92.2% of Australian children were fully immunised against pertussis (three doses 
of DTPa-containing vaccine) at 12 months of age.62 Coverage estimates for birth cohorts 
at 12 months of age have remained relatively stable, at approximately 92%, since 
2001.62,148 Nationally, the proportion of five year old children who were fully vaccinated 
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against pertussis (defined as four or five doses of a DTPa-containing vaccine) in 2012 was 
slightly lower at 91.7%.62  
Although the Australian National Immunisation Schedule includes adolescent doses, the 
ACIR to date has not been able to record them, making adolescent coverage estimates 
more challenging. In Australia adolescent vaccinations are administered in school-based 
programs and the providers of these programs must report coverage. Jurisdictions vary in 
their implementation of school-based programs, with the most notable difference being the 
target age (or school year) for vaccination. In 2009, the adolescent dTpa coverage ranged 
between 62-81% across Australia, which was consistent with coverage estimates in 
2005-2008 (for States and Territories where data were available). Data about adolescent 
vaccinations administered outside the school setting are limited,149,150 however a 
randomised cluster survey conducted in Victoria estimated that in 2009, 11.4% of the 
15 year old population were immunised in the GP setting.150   
In Australia, due to the ad hoc nature of adult immunisation and the absence of a 
whole-of-life register, it is also not currently possible to obtain adult pertussis coverage 
estimates.62 Although coverage in this group is likely to be low, having a whole-of-life 
immunisation register would make it possible to monitor uptake of adult booster doses and 
maternal vaccinations, rather than having to conduct labour-intensive studies. In 2015, it 
was announced that the ACIR would be gradually expanded to a whole-of-life 
immunisation register which, once implemented, will provide information about adolescent 
and adult vaccination uptake.151 
Vaccination coverage and timeliness in children are generally comparable between 
Australia and other developed countries (e.g. Korea, Japan, Switzerland, Spain, Germany, 
Austria, France, and Finland), with coverage considerably lower in developing countries 
where there are significant barriers to implementation of vaccine 
recommendations.33,57,148,152-170  
Diagnosis 
There are several diagnostic methods available for laboratory detection and confirmation 
of B. pertussis infection. During the early stage of infection, where symptoms are similar to 
a common cold, pertussis organisms are present in high quantities in nasopharyngeal 
samples which allows testing using culture, antigen detection, or polymerase chain 
reaction (PCR) methods. By the time the cough develops, the number of organisms in the 
CHAPTER 1 
 
16 
nasopharynx has often decreased to undetectable levels, making serology a more 
sensitive diagnostic option. Therefore, the ideal diagnostic method can be dependent on 
the timing of testing (diagnostic sample collection) relative to illness symptoms or disease 
onset.2,3,29,171  
Culture 
The diagnostic gold standard for pertussis diagnosis has historically been bacterial culture 
from nasopharyngeal secretions (NPS) during the early phases, specifically in the first one 
to two weeks, of pertussis infection.2,3,10,51,172 
For the best chance of detecting B. pertussis, a nasopharyngeal aspirate specimen, 
obtained early during the illness course, is inoculated immediately onto pertussis-specific 
culture media and transported under ideal conditions to the laboratory. Pertussis-specific 
media, containing antibiotics such as cloxacillin and cephalexin, is required to suppress 
growth of other respiratory pathogens and allow B. pertussis to grow.2,171,172 Although 
culture typically takes three to seven days to become positive, it can take up to several 
weeks for conclusive results, by which time the patient may have already recovered or it 
may be too late to commence them on treatment, and it would also delay any required 
public health response.2,10,172 
Unfortunately, B. pertussis is highly fastidious and it is very difficult to grow on culture even 
under ideal circumstances. The likelihood of detection using culture decreases with time 
from illness onset, with specimens collected later, especially following the onset of cough, 
significantly less likely to produce organisms. In addition, positive culture is less likely in 
immunised individuals and with increasing patient age. Even though culture is still 
considered the gold standard for pertussis diagnosis, due to its low sensitivity, very 
specific medium and transport requirements, and inability to provide timely results, other 
methods such as PCR and serology are now more commonly used.2,10,172  
Serology 
Diagnosis using serology requires collection of a blood sample from which serum is 
extracted and tested for antibody levels to B. pertussis using one (or more) of the following 
methods: complement fixation, agglutination, toxin neutralization, or enzyme-linked 
immunosorbent assays (ELISAs). ELISAs are most commonly used for diagnosis, as they 
are the easiest to perform and standardise, and have the ability to detect specific 
immunoglobulin isotype responses and measure serum antibodies against specific 
antigens of B. pertussis. Definitive diagnosis using serology requires a specific-fold 
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increase in antibodies between paired samples, taken during the acute and convalescent 
stages of illness, but can also be based on a single high-titre result.2,10,171-173 
The benefit of serology is that it can detect infection in vaccinated individuals as well as 
those who had asymptomatic, mild or atypical illness, and it avoids the lack of sensitivity 
and other known limitations of culture. Serology is often used to monitor immune 
responses in vaccine clinical trials, and can also be used to conduct serosurveys to 
determine prevalence of antibodies across different age groups, especially following 
outbreaks or immunisation schedule changes.2,10,111,173  
The greatest disadvantage of serology is that performance of the method, and therefore 
diagnosis, is dependent on the definition used; methods and definitions differ between 
laboratories. The timing of sample collection is also important, as samples taken too early 
or too late may produce false negatives. Furthermore, serology may not be an appropriate 
diagnostic method for individuals who were recently immunised, as vaccination (like 
infection) leads to increases in antibody titres which may be interpreted as false 
positives.2,10,172 
Antigen detection 
The direct fluorescent antibody (DFA) test was once used for pertussis diagnosis. This 
method involved nasopharyngeal swabs that were smeared onto slides and heat-fixed. 
Slides were then stained with fluorescein isothiocyanate-conjugated B. pertussis 
antiserum, viewed under a microscope, and scored according to their level of 
fluorescence.174 
The specificity of DFA is highly variable due to the subjective interpretation of test results, 
and sensitivity is lower than culture.2,174 As such, DFA was considered to be most useful 
when combined with either culture or serology for the diagnosis of pertussis cases.174 A 
DFA-positive result alone, without confirmation by another diagnostic method, does not 
meet the confirmed pertussis case definition for notification in the United States or 
Australia.175,176 
PCR methods 
PCR assays have been developed to identify unique gene sequences of B. pertussis in 
respiratory secretions.2,3,10,11,23,174,177,178 Samples for PCR testing are ideally collected as 
nasopharyngeal swabs (NPS) or nasopharyngeal aspirates (NPA). Although PCR methods 
can differ between laboratories, the use of real-time PCR (RT-PCR) is preferred.175,178 This 
method commonly utilises commercial DNA extraction kits as well as B. pertussis PCR 
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assay kits which amplify and detect B. pertussis DNA sequence-specific targets.178 Most 
PCR assays are based on the detection of the insertion sequence (IS) elements IS 481 
and IS 1002, because there are multiple copies of these sequences in the Bordetella 
chromosome.179 Higher numbers of PCR target sequence copies within a chromosome 
improve the sensitivity of the PCR assay.179 Although a large number of PCR assays have 
been described for the detection of B. pertussis as well as B. parapertussis and 
B. holmesii,179-183 as there is limited genetic diversity between Bordetella species,179-183 
PCR assays for B. pertussis that use IS 481 and/or IS 1002 lack specificity and are likely 
to return false positive results for samples containing other Bordetella species.179 For 
example, IS 481 is found in both B. pertussis and B. holmesii, and IS 1002 is common to 
both B. pertussis and B. parapertussis.179 While it is thought that the likelihood of other 
Bordetella species causing pertussis-like illness is low,13,175,178,179,181,183,184 newer assays 
with improved specificity (without compromising sensitivity) are being developed.179 
Compared to other diagnostic methods, PCR testing has many benefits: it is rapid (one to 
two day turn-around), highly sensitive and specific, PCR can remain positive even after 
antibiotic treatment has commenced, and like serology, PCR testing can detect 
asymptomatic and mild cases.2,10,23,171,172,174,185,186 Due to the advantages of PCR, 
compared to culture and serology, it is becoming the preferred diagnostic method for 
pertussis diagnosis worldwide.2,3,10,11,23,177  
In Australia, the availability of PCR for diagnosis of pertussis has increased over the last 
decade. Public funding for laboratories to test specimens using PCR commenced under 
the Australian Government-funded Medicare Benefits Schedule (MBS) in 2005.187 
Additionally, specific funding was provided for laboratories to purchase equipment, 
primarily for PCR, during the 2009 H1N1 influenza pandemic, which expanded PCR 
diagnostic capacity within laboratories.188  
Public Health Significance 
In addition to government-funded vaccinations and health-care costs, significant public 
health resources are devoted to case follow-up, outbreak investigation, and surveillance 
activities.  
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Public health response 
National guidelines for the management of pertussis cases and outbreaks were developed 
by the Communicable Diseases Network of Australia – a committee made up of 
representatives from each State and Territory government, the Commonwealth 
government, and other relevant organisations.21,23  
Pertussis cases in children younger than five years of age, and particularly infants younger 
than one year of age, are routinely followed up by public health units. Cases (or their 
carers) are contacted in order to obtain further information, which is then used to 
determine the level of public health intervention required to prevent transmission to any 
high risk contacts. High risk contacts include, but are not limited to, children younger than 
24 months of age who have received less than three effective vaccine doses, women in 
the last month of pregnancy, childcare staff who have not been vaccinated in the previous 
10 years, and healthcare staff who work in maternity hospitals or newborn nurseries.21,23 
Public health staff endeavour to determine the likely source of infection, verify vaccination 
status, confirm the symptoms and illness onset, as well as identify and obtain details of 
possible contacts.21,23 It is strongly recommended that cases are isolated and/or excluded 
from activities where they may come into contact with young infants or other high risk 
individuals.23 Antibiotic prophylaxis, using macrolides (azithromycin, clarithromycin, or 
erythromycin) or a non-macrolide alternative (trimethoprim and sulfamethoxazole), is 
recommended for high risk contacts, including infants younger than six months of age or 
those who might transmit pertussis to these infants.189 
Where outbreaks are identified, additional control measures may be required, such as 
active case finding, epidemiological studies to determine risk factors, distribution of 
information and alerts to healthcare professionals and the community, and immunisation of 
those at risk.4,23  
Similar guidelines for public health response to pertussis are used across other developed 
countries, including the United States, Canada, United Kingdom, and parts of Europe.10 
Surveillance 
Many countries, including Australia, have well developed surveillance systems in place to 
monitor pertussis epidemiology and evaluate the effectiveness of control strategies, such 
as immunisation.7,190-192 Surveillance systems are often resource intensive, particularly 
those that rely on laboratory diagnosis and notification, and add to the already significant 
public health and healthcare costs associated with pertussis.190-192  
CHAPTER 1 
 
20 
In Australia, pertussis was made nationally notifiable in 1991, requiring mandatory 
reporting of all cases that meet a standard case definition to State/Territory health 
departments.175 A case meets the current Australian pertussis case definition if there is 
either laboratory definitive evidence or a combination of laboratory suggestive evidence 
with clinical evidence. Laboratory definitive evidence includes isolation of B. pertussis, 
detection of B. pertussis by nucleic acid testing, or seroconversion in paired sera for 
B. pertussis using whole cell or specific B. pertussis antigen(s) in absence of recent 
pertussis vaccination. Laboratory suggestive evidence required for notification, in absence 
of recent vaccination, includes a significant change (increase or decrease) in antibody 
level (IgG, IgA) to B. pertussis whole cell or B. pertussis specific antigen(s), or a single 
high IgG and/or IgA titre to Pertussis Toxin (PT), or a single high IgA titre to whole cell 
B. pertussis antigen. Clinical evidence requires coughing illness lasting two or more weeks 
or paroxysms of coughing, inspiratory whoop, or post-tussive vomiting.175 
Australian pertussis surveillance is conducted using a passive system, and relies on 
mandatory national notification data. For pertussis cases to be notified, patients must 
present to healthcare providers and have diagnostic tests done, which, if positive, will be 
reported to the appropriate State/Territory health department. This system is therefore 
likely to under-report the true incidence of pertussis cases, as those who do not present, 
are not tested, or have false negative results, are not counted. Additionally, passive 
systems can also be biased by changes in case ascertainment, which can occur as a 
result of improved diagnostic methods, increased diagnostic testing, and/or increased 
awareness.7,190-193  
Although notifications cover the full spectrum of clinical illness, they do not differentiate 
cases with mild symptoms from those with severe symptoms. There is no specific national 
surveillance system in Australia that quantifies pertussis hospitalisations or deaths. As 
such, reporting of hospitalisations is generally ad hoc, limited to a distinct geographic 
location or time period, and highly resource intensive.8,60,89,105,177,194  
Pertussis surveillance in Australia is similar to that in Canada, the United States, the 
United Kingdom and other developed countries, however reports of pertussis activity can 
vary widely between these locations.7,190 Variations between countries can be due to 
differences in case definitions, laboratory methods, system design, surveillance goals  
(e.g. identify every case, large outbreaks, or vaccine failures only), available resources, 
and mandatory notification requirements.7 These differences make it difficult to compare 
incidence rates, transmission patterns, and overall disease burden between  
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countries.7,190-192 Passive or sentinel surveillance systems are often used to capture 
hospitalisations and deaths, however these systems are also likely to under-estimate 
disease burden.85,177,190-192,195-200 
Gaps in current knowledge 
Despite long-standing, successful immunisation programs in Australia and overseas, over 
the last decade pertussis incidence has increased, with large sustained epidemics 
occurring most notably in developed countries.5-7 This resurgence of pertussis raised 
concerns about the effectiveness of existing pertussis control strategies.10,52 At the 
commencement of this PhD, the drivers behind the global pertussis resurgence were 
unclear. It was hypothesised that the resurgence may be attributed to numerous factors 
including: improved diagnostic methods and case detection, declining vaccine coverage, 
changes in immunisation schedules, changes in vaccine formulations (whole cell to 
acellular), waning of vaccine-derived immunity, or B. pertussis strain variation.6,7,9,10,52,190 
Given the breadth of these possible contributing factors, it was not feasible to attempt to 
address them all within the scope of one PhD. As such, the studies contained within this 
Thesis are focused on exploring changes to pertussis diagnostic methods, and the impact 
these changes have had on the epidemiology of pertussis in Australia, including during the 
recent resurgence.  
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Chapter 2 – The contribution of PCR testing to influenza and 
pertussis notifications in Australia  
 
 
This chapter is presented as a published original research article: 
Kaczmarek MC, Ware RS, Lambert SB. The contribution of PCR testing to influenza and 
pertussis notifications in Australia. Epidemiology and Infection. 2016; 144(2):306-314. 
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SUMMARY 
Influenza and pertussis are the two most common vaccine-preventable infections notified 
in Australia. We assessed the role of polymerase chain reaction (PCR) diagnosis in 
influenza and pertussis cases notified to the Australian National Notifiable Diseases 
Surveillance System (NNDSS). There were a total of 210,786 notified influenza cases 
(2001-2013) and 255,866 notified pertussis cases (1991-2013). After 01 January 2007, the 
majority of influenza and pertussis notifications were PCR-based (80.5% and 59.6%, 
respectively). Before 31 December 2006, PCR-based notifications were limited (29.1% 
and 11.7%, respectively). By 2013, PCR-based notifications had largely replaced all other 
diagnostic methods, with the exception of serology-based notifications among pertussis 
cases in adults aged ≥25 years.  
HIGHLIGHTS 
• We assessed the patterns of notified pertussis and influenza cases in Australia.  
• Our aim was to explore changes in PCR-based notifications. 
• A dramatic increase in the number and proportion of PCR-based notifications was 
observed over the study period.  
• By 2013, PCR-based notifications had largely replaced all other diagnostic methods 
for influenza and pertussis, other than among a substantial proportion of adult 
pertussis cases which remained serology-based. 
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INTRODUCTION 
Influenza and pertussis are the two most common vaccine-preventable infections notified 
in Australia.64 The clinical illness for both influenza and pertussis infections range from 
mild to severe, and asymptomatic cases can occur across all age groups, and may not be 
uncommon.201,202  
Both influenza and pertussis are nationally notifiable in Australia according to State and 
Territory legislation. For notification, cases must meet the case definitions which require 
laboratory evidence of infection, with acceptable testing methods including polymerase 
chain reaction (PCR), culture, antigen detection, and serology.175,203  
Compared to culture and serology, PCR testing is more sensitive and has a faster turn-
around time for results.204 In Australia, the availability of PCR for diagnosis of influenza 
and pertussis has increased over the last decade. Public funding for laboratories to test 
specimens using PCR commenced under the Australian Government-funded Medicare 
Benefits Schedule in 2005.187 Additionally, public funding was provided for laboratories to 
purchase equipment, primarily for PCR, during the 2009 H1N1 influenza pandemic.188  
Since 2007, increased influenza and pertussis incidence has been associated with a 
pertussis epidemic (2009 to 2012) caused in part by waning immunity, and an influenza 
pandemic (2009) caused by the circulation of a novel virus strain.64,92 The role of improved 
availability of PCR testing has been hypothesized to have led to improved case 
ascertainment and improved detection of disease activity.64,205 
With this study, we describe patterns of notified pertussis and influenza cases in Australia, 
and explore the role of newer laboratory diagnostic methods in any changes. 
METHODS 
All available pertussis and influenza notifications were obtained from the National 
Notifiable Diseases Surveillance System (NNDSS). Both are notifiable conditions under 
Public Health legislation in each State and Territory in Australia, and all cases that meet 
the case definition are required to be notified to the State and Territory Health 
Departments.203 The Australian Government Department of Health aggregates state 
notification data in the NNDSS.  
Influenza has been nationally notifiable since 2001 and a confirmed case of influenza 
requires a laboratory diagnosis. Definitive laboratory evidence for notification consists of 
CHAPTER 2 
 
26 
isolation of influenza virus by culture, detection of influenza virus by nucleic acid testing, or 
laboratory detection of influenza virus antigen. Alternatively, serology for notification 
requires IgG seroconversion, a significant increase in antibody level or a fourfold or greater 
rise in titre to influenza virus, or a single high titre by complement fixation testing or 
haemagglutination inhibition assay to influenza virus.203 
Pertussis was made nationally notifiable in 1991, and a case meets the definition if there is 
either laboratory definitive evidence or a combination of laboratory suggestive evidence 
with clinical evidence. Laboratory definitive evidence includes isolation of 
Bordetella pertussis by culture, detection of B. pertussis by nucleic acid testing, or 
seroconversion in paired sera for B. pertussis using whole cell or specific B. pertussis 
antigen(s) in absence of recent pertussis vaccination. Laboratory suggestive evidence 
required for notification, in absence of recent vaccination, includes a significant change 
(increase or decrease) in antibody level (IgG, IgA) to B. pertussis whole cell or B. pertussis 
specific antigen(s), or a single high IgG and/or IgA titre to pertussis toxin, or a single high 
IgA titre to whole cell B. pertussis antigen. Clinical evidence requires coughing illness 
lasting two or more weeks or paroxysms of coughing, inspiratory whoop or post-tussive 
vomiting.175 
Line listed data were provided for each notification, rather than each individual case, as 
cases could be notified in duplicate following different diagnostic tests. Duplicate 
notifications, where a case was diagnosed using more than one diagnostic method and 
therefore notified more than once, were combined into a single record. Notifications with 
laboratory testing methods of histopathology, microscopy, ‘other’ or ‘unknown’ were 
excluded, as the former two no longer meet the case definition and it is uncertain whether 
the latter two meet the case definition. During analysis, data were aggregated by 
diagnostic method, year and age groups (<1 year, 1 to <5 years, 5 to <10 years, 10 to <15 
years, 15 to <25 years, ≥25 years). Annual age-group specific incidence rates per 100,000 
population were calculated using Australian Bureau of Statistics population estimates.206 
For simplicity, duplicate notifications were grouped into ‘Multiple methods (PCR)’ if PCR 
was one of the diagnostic methods used, or ‘Multiple methods (other)’ if any combination 
of tests not including PCR were used. Data were also aggregated into the pre-PCR era 
(≤31 December 2006) and PCR era (≥01 January 2007). Although funding became 
available in late 2005 for PCR testing,187 the PCR-era was defined as beginning 
01 January 2007 as it took time for laboratories to purchase equipment and liaise with 
clinicians to change sample collection protocols. Total PCR-based notifications (PCR only 
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notifications combined with duplicate notifications where PCR was one of the methods 
used) were compared with all other single and duplicate non-PCR notifications (‘All non-
PCR methods’).  
Ethics approvals for this study were obtained from the ACT Health Human Research 
Ethics Committee and The University of Queensland School of Public Health Research 
Ethics Committee. 
RESULTS 
A total of 210,786 influenza cases and 255,866 pertussis cases were notified over the 
study period (influenza: 01/01/2001 to 31/12/2013; pertussis: 01/01/1991 to 31/12/2013) 
(Table 1). Of these, 12,666 (6.0%) influenza and 64,438 (25.2%) pertussis notifications 
were excluded, predominantly because they had an ‘unknown’ diagnosis method (85.5% 
and 99.4%, respectively). Excluded notifications were approximately equally distributed 
across all age groups but primarily occurred in the pre-PCR era (<2007) rather than during 
the PCR era (≥2007; influenza: 18.8% vs 4.8%; pertussis: 48.2% vs 25.2%, respectively). 
The majority of influenza and pertussis cases were notified following a single diagnostic 
test (92.8% and 98.0%, respectively). During the PCR era, the majority of influenza and 
pertussis notifications were PCR-based (80.5% and 59.6%, respectively), with serology 
largely responsible for the remainder of notifications (12.3% and 39.9%, respectively).  
There was variation in the median age of notifications, with individuals whose notification 
was based on PCR methods consistently younger than individuals whose notification was 
based on non-PCR methods (Table 2). The age difference between individuals with PCR 
and non-PCR-based notifications increased in the PCR-era for both influenza and 
pertussis cases. The incidence rate of influenza and pertussis notifications (per 100,000 
age group-specific population per year) increased in all age groups (Figure 2 and 
Figure 3).  
Between the pre-PCR era and PCR era there was a 3.1 fold increase (95% confidence 
interval (CI): 3.0 - 3.1) in the proportion of influenza PCR-based notifications and an 
8.7 fold increase (95% CI: 8.5 – 9.0) in the proportion of pertussis PCR-based notifications 
(Table 3). The proportion of all non-PCR-based notifications decreased 0.4 fold for 
influenza notifications and 0.5 fold for pertussis notifications. The highest increases in the 
proportion of PCR-based notifications were among children aged 1 to <5 years (influenza) 
and 5 to <10 years (pertussis).  
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Diagnostic methods varied by age group over the study period (Figure 4 and Figure 5). 
From 2001, there was a gradual increase in the proportion of PCR-based notifications in 
all age groups; however, from 2007, a dramatic increase was observed in all age groups 
for influenza and younger age groups (<15 years) for pertussis. Although the proportion of 
PCR-based pertussis notifications also increased among individuals aged ≥15 years, a 
large proportion of notifications in the 15 to <25 and ≥25 year age groups remained 
serology-based in the PCR era. The proportion of culture, serology and antigen detection-
based notifications in influenza cases and younger pertussis cases declined over the study 
period. 
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Table 1: Influenza and pertussis notifications, by diagnostic method and time period, to 31 December 2013, Australia 
 
Influenza (from 01 January 2001) 
n (%) 
Pertussis (from 01 January 1991) 
n (%) 
≤31 December 2006 ≥01 January 2007 TOTAL ≤31 December 2006 ≥01 January 2007 TOTAL 
Total single 
diagnostic method 
used 
13,219 (88.5%) 170,589 (93.1%) 183,808 (92.8%) 49,175 (98.3%) 138,515 (98.0%) 187,690 (98.0%) 
PCR only 3,442 (23.0%) 135,620 (74.0%) 139,062 (70.2%) 5,052 (10.1%) 81,404 (57.6%) 86,456 (45.2%) 
Culture only 2,061 (13.8%) 5,527 (3.0%) 7,588 (3.8%) 1,309 (2.6%) 283 (0.2%) 1,592 (0.8%) 
Serology only 5,395 (36.1%) 22,495 (12.3%) 27,890 (14.1%) 41,537 (83.0%) 56,466 (39.9%) 98,003 (51.2%) 
Antigen detection 
only 2,321 (15.5%) 6,947 (3.8%) 9,268 (4.7%) 1,277 (2.6%) 362 (0.3%) 1,639 (0.9%) 
Total multiple 
diagnostic methods 
used 
1,715 (11.5%) 12,597 (6.9%) 14,312 (7.2%) 841 (1.7%) 2,897 (2.0%) 3,738 (2.0%) 
Multiple methods – 
PCR* 907 (6.1%) 11,897 (6.5%) 12,804 (6.5%) 787 (1.6%) 2,818 (2.0%) 3,605 (1.9%) 
Multiple methods – 
other† 808 (5.4%) 700 (0.4%) 1,508 (0.8%) 54 (0.1%) 79 (0.1%) 133 (0.1%) 
Total included 
notifications 14,934 (100.0%) 183,186 (100.0%) 198,120 (100%) 50,016 (100.0%) 141,412 (100.0%) 191,428 (100%) 
Total PCR-based 
notifications‡ 4,349 (29.1%) 147,517 (80.5%) 151,866 (76.7%) 5,839 (11.7%) 84,222 (59.6%) 90,061 (47.0%) 
Excluded 
notifications§ 3,462 9,204 12,666 46,564 17,874 64,438 
 
* Includes all notifications where PCR was used in combination with culture, serology and/or antigen detection. 
† Includes any combination of culture, serology and/or antigen detection-based notifications, without PCR testing. 
‡ Includes all ‘PCR only’ and ‘Multiple methods – PCR’ notifications. 
§ Excluded notifications include those with a laboratory method of histopathology, microscopy, ‘other’ or ‘unknown’.  
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Table 2: Median and mean age of influenza and pertussis notifications, by diagnostic method and time period, to 
31 December 2013*, Australia 
 
≤31 December 2006 ≥01 January 2007 TOTAL 
PCR† All non-PCR methods‡ PCR† All non-PCR methods‡ PCR† All non-PCR methods‡ 
Influenza median age 
(Mean) 
18 years 
(25.4 years) 
19 years 
(27.6 years) 
25 years 
(28.8 years) 
34 years 
(35.7 years) 
24 years 
(27.8 years) 
31 years 
(33.8 years) 
Pertussis median age 
(Mean) 
13 years 
(19.9 years) 
28 years 
(30.5 years) 
10 years 
(19.1 years) 
46 years 
(44.7 years) 
10 years 
(19.1 years) 
38 years 
(36.9 years) 
 
* Influenza reporting period: 01/01/2001 to 31/12/2013; Pertussis reporting period: 01/01/1991 to 31/12/2013 
† ‘PCR’ includes all notifications where PCR was used as diagnostic method (irrespective of whether the sole method or in combination with other methods). 
‡ ‘All other methods’ includes all culture, serology and/or antigen detection-based notifications, including any combination of these diagnostic methods, without PCR 
testing. 
CHAPTER 2 
 
31 
Figure 2: Annual influenza notification rate per 100,000 age-specific population, 1 January 2001 to 31 December 2013, Australia  
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Figure 3: Annual pertussis notification rate per 100,000 age-specific population, 1 January 1991 to 31 December 2013, Australia  
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Table 3: Influenza and pertussis notifications, by age group, diagnostic method and time period, to 31 December 2013, Australia 
Age Group 
≤31 December 2006 ≥01 January 2007 
TOTAL Fold difference in number of PCR tests*† 
Relative difference 
in % PCR*† 
(95% CI) 
Relative difference in % all 
non-PCR methods*‡  
(95% CI) 
Absolute difference in PCR*‡  
(95% CI) 
PCR† All non-PCR methods‡ PCR† All non-PCR methods‡ 
INFLUENZA (from 01/01/2001) 
<1 year 507  (22.5%) 
1,742 
(77.5%) 
4,500 
(76.2%) 
1,408 
(23.8%) 
8,157 8.9 
3.4 
(3.1 - 3.6) 
0.3 
(0.3 - 0.3) 
53.6% 
(51.2% - 55.7%) 
1 to <5 years 
849 
(23.5%) 
2,765 
(76.5%) 
15,664 
(82.6%) 
3,309 
(17.4%) 
22,587 18.4 3.5 (3.3 - 3.7) 
0.2 
(0.2 - 0.2) 
59.1% 
(57.6% - 60.5%) 
5 to <10 years 
355 
(27.1%) 
956 
(72.9%) 
18,176 
(86.1%) 
2,932 
(13.9%) 
22,419 51.2 3.2 (2.9 - 3.5) 
0.2 
(0.2 - 0.2) 
59.0% 
(56.6% - 61.5%) 
10 to <15 years 
293 
(27.3%) 
779 
(72.7%) 
13,275 
(82.9%) 
2,746 
(17.1%) 
17,093 45.3 3.0 (2.7 - 3.3) 
0.2 
(0.2 - 0.2) 
55.5% 
(52.8% - 58.2%) 
15 to <25 years 
534 
(27.1%) 
1,439 
(72.9%) 
21,822 
(77.4%) 
6,358 
(22.6%) 
30,153 40.9 2.9 (2.7 - 3.1) 
0.3 
(0.3 - 0.3) 
50.4% 
(48.3% - 52.4%) 
≥25 years 
1,824 
(22.3%) 
6,354 
(77.7%) 
74,187 
(65.7%) 
38,638 
(34.2%) 
121,003 40.7 2.9 (2.8 - 3.1) 
0.4 
(0.4 - 0.4) 
43.4% 
(42.5% - 45.0%) 
TOTAL 
4,362 
(23.7%) 
14,035 
(76.3%) 
147,624 
(72.7%) 
55,391 
(27.3%) 
221,412 33.8 3.1 (3.0 - 3.1) 
0.4 
(0.3 - 0.4) 
49.0% 
(48.4% - 49.6%) 
PERTUSSIS (from 01/01/1991) 
<1 year 
956 
(24.7%) 
2,913 
(75.3%) 
4,675 
(93.6%) 
320 
(6.4%) 
8,864 4.9 3.8 (3.6 - 4.0) 
0.1 
(0.1 - 0.1) 
68.9% 
(67.4% - 70.4%) 
1 to <5 years 
693 
(13.2%) 
4,554 
(86.8%) 
12,520 
(88.8%) 
1,583 
(11.2%) 
19,350 18.1 6.7 (6.3 - 7.2) 
0.1 
(0.1 - 0.1) 
75.6% 
(74.5% - 76.6%) 
5 to <10 years 
503 
(4.9%) 
9,799 
(95.1%) 
21,962 
(87.7%) 
3,067 
(12.3%) 
35,331 43.7 18.0 (16.5 - 19.6) 
0.1 
(0.1 - 0.1) 
82.9% 
(82.3% - 83.4%) 
10 to <15 years 
1,066 
(6.8%) 
14,583 
(93.2%) 
14,945 
(77.1%) 
4,435 
(22.9%) 
35,029 14.0 11.3 (10.7 - 12.0) 
0.2 
(0.2 - 0.2) 
70.3% 
(69.6% - 71.0%) 
15 to <25 years 
734 
(6.5%) 
10,643 
(93.5%) 
5,452 
(49.0%) 
5,665 
(51.0%) 
22,494 7.4 7.6 (7.1 - 8.2) 
0.5 
(0.5 - 0.5) 
42.6% 
(41.6% - 43.6%) 
≥25 years 
1,889 
(3.8%) 
48,247 
(96.2%) 
24,674 
(29.1%) 
59,988 
(70.9%) 
134,798 13.1 7.7 (7.3 - 8.1) 
0.7 
(0.7 - 0.7) 
25.4% 
(25.0% - 25.7%) 
TOTAL 
5,841 
(6.1%) 
90,739 
(93.9%) 
84,228 
(52.9%) 
75,058 
(47.1%) 
255,866 14.4 8.7 (8.5 - 9.0) 
0.5 
(0.5 - 0.5) 
46.8% 
(46.5% - 47.1%) 
 
* Comparison between ≤31 December 2006 and ≥01 January 2007 
† ‘PCR’ includes all notifications where PCR was used as diagnostic method (irrespective of whether the sole method or one of a combination). 
‡ ‘All non-PCR methods’ includes all culture, serology and/or antigen detection-based notifications, including and combination of these diagnostic methods, without PCR tests. 
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Figure 4: Notifications of influenza by diagnostic method and year, 01 January 2001 to 31 December 2013, Australia, with 
percent of notifications on the left axis and total number of notifications on the right axis. 
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Figure 5: Notifications of pertussis by diagnostic method and year, 01 January 1991 to 31 December 2013, Australia, with 
percent of notifications on the left axis and total number of notifications on the right axis. 
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DISCUSSION 
PCR-based influenza and pertussis notifications have increased substantially in Australia 
over the study period. In the PCR era (≥2007), the proportion of notifications that were 
PCR-based for influenza and pertussis was 3.1- and 8.7-fold higher, respectively, 
compared with the pre-PCR era. The largest increase in the proportion of PCR-based 
notifications was in children aged 5 to <10 years. By 2013, the majority of notifications 
were PCR-based and PCR had largely replaced all other diagnostic methods, other than 
among pertussis cases aged ≥25 years, which remain predominantly serology-based 
(68.5% in 2013).  
PCR has provided an opportunity to increase testing due to its advantages over previously 
available diagnostic methods. In Australia in the pre-PCR era, culture, antigen detection, 
and serology were the primary methods for diagnosing influenza and pertussis. Serology is 
generally rejected for younger age groups who are more likely to present during acute 
illness, and has primarily been (and continues to be) used among older age groups for 
retrospective diagnosis, especially for pertussis.172,207 Culture and antigen detection can 
be used during acute illness, however both of these methods have limitations. Culture 
(particularly for pertussis) requires high quality specimens, is time consuming, difficult, 
costly, and has been increasingly rarely offered over time.172,207,208 Antigen detection is 
generally not available for pertussis, while for influenza, it has lower sensitivity than culture 
or PCR, is not routinely used in Australia, and can be expensive.208 Comparatively, PCR 
provides highly sensitive and specific, rapid, inexpensive diagnostic testing, with fewer 
specimen collection, quality or transport requirements.172,208 It is therefore not surprising 
that the use of PCR has increased dramatically over time, or that it has replaced other 
diagnostic methods.  
The expansion of PCR-based testing and the impact on notifications seen in our study 
may, at least in part, explain changes in the observed epidemiology of pertussis and 
influenza that occurred over the study period. In the pre-PCR era, both pertussis and 
influenza had different age distributions, with incidence rates highest in very young 
children.209 During the PCR era, a growing proportion of notifications have occurred in 
older children.64 Our results highlight that PCR has provided the opportunity to test and 
notify cases in age groups (particularly 5 to <10 year olds) who previously have had low 
notification rates. Increasing incidence of influenza and pertussis notifications may also be 
partially attributed to changes in diagnostics, with PCR providing the opportunity to test 
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more broadly. Previous Australian studies have observed an increase in the total number 
of pertussis and influenza diagnostic tests performed since 2007, and a seven-fold rise in 
the likelihood of having a pertussis diagnostic test ordered in the primary care setting 
between 2000-2004 and 2010-2011.205,210 
However, expanding availability and use of PCR did not occur in isolation, and there are 
other factors that are likely to have contributed to increased PCR-based notifications. In 
recent years, Australia has experienced a pertussis epidemic (2009 to 2012) and influenza 
pandemic (2009).64 The pertussis epidemic has in part been attributed to waning immunity 
among older children who received complete courses of acellular vaccine, while the impact 
of the influenza pandemic was due to a novel strain to which children and younger adults 
were more susceptible.64,92 While the pathogen-host interactions were responsible for 
changes in incidence and demographics, we argue that without the increased availability 
of PCR, it would have been more difficult to detect these changes. Additionally, there was 
substantial media attention about pertussis and influenza during peak periods of activity 
and following deaths in young infants. Improved awareness, whether following media 
attention or training, has been found to increase diagnostic testing, through changed 
patient and clinician behaviour.193,211-213 Moreover, the combination of improved PCR 
availability, better awareness and increased circulation of pathogens, is likely to have 
created a positive feedback loop, ultimately leading to more testing over time. Although 
negative test results following the end of an epidemic could create a negative feedback 
loop, the improved awareness gained throughout the epidemic could lead clinicians to 
continue testing clinically compatible cases during inter-epidemic periods. Ultimately, 
increases and decreases in pertussis notifications, particularly during epidemic periods, 
would be better understood by knowing the total number of tests ordered and the 
proportion of those tests that were positive for pertussis.214 
Overall, increasing PCR use has probably improved case detection for notifiable infections 
such as influenza and pertussis. The purpose of infectious disease surveillance is to 
monitor trends, detect outbreaks, and both guide and evaluate public health responses. 
While at a national level the NNDSS functions very well to achieve these goals, as a 
passive surveillance system it is prone to case under-ascertainment and has lower 
sensitivity than an active surveillance system. Over our study period, the changes in the 
use of PCR, along with increased awareness of the illnesses, would have improved 
NNDSS case ascertainment, sensitivity, and representativeness. There would also have 
been a reduction in ascertainment bias, as PCR allows more widespread testing (and 
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therefore notification) of cases across the population. Although it is unlikely that PCR use 
will decline in the near future, we hypothesise that the increase in testing will eventually 
plateau and set a new higher background incidence for pertussis and influenza. Once that 
occurs, it will be easier to identify true increases in incidence without the influence of 
changes in testing and awareness.  
We have demonstrated the role that increased PCR use has had on observed pertussis 
and influenza epidemiology, however this phenomenon is not limited to Australia. Globally, 
other countries with increasing PCR use have reported similar changes to observed 
pertussis incidence and demographics.6,11 As PCR testing is expanded to other 
pathogens, such as those that cause gastrointestinal infections,215,216 changes to the 
infection epidemiology are likely to be observed. When relying on a laboratory-based 
surveillance system, any changes in disease epidemiology need to be interpreted in 
conjunction with knowledge of underlying testing patterns.   
CONCLUSION 
In Australia, PCR-based influenza and pertussis notifications have been increasing since 
2001 across all age groups. By 2013, PCR-based notifications had largely replaced all 
other diagnostic methods, with the exception of serology-based notifications among older 
pertussis cases. 
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ABSTRACT 
Objective: To better understand the role that diagnostic test-ordering behaviour of general 
practitioners has on current pertussis epidemiology in Australia. 
Design and Setting: Analysis of Australian general practice encounter data (from the 
Bettering the Evaluation and Care of Health [BEACH] program) on 13 “pertussis-related 
problem” (PRP) codes that were most likely to result in a pertussis laboratory test request 
and Australian pertussis notifications data (from the National Notifiable Diseases 
Surveillance System [NNDSS]) for the period April 2000 to March 2011. 
Main Outcome Measures: The change in the proportion of PRP general practice 
encounters with a pertussis test request between 2000 and 2011, and the change in 
national pertussis notifications over the same time period.  
Results: The proportion of PRP encounters resulting in a pertussis test request increased 
from 0.25% between April 2000 and March 2004, to 1.71% between April 2010 and 
March 2011 (odds ratio: 7.0; 95% confidence interval (CI): 5.5–8.8). The BEACH data on 
pertussis testing and NNDSS data on pertussis notifications were highly correlated 
(r=0.99), and the notification data mirrored the likelihood of a pertussis test request in 
general practice. The proportion of NNDSS notifications with a polymerase chain reaction 
(PCR) confirmed diagnosis increased from 16.3% between April 2000 and March 2004, to 
65.3% between April 2010 and March 2011. 
Conclusion: An increase in testing following recognition of early epidemic cases may have 
led to identification of previously undetected infections, resulting in a further increase in 
notified disease and awareness among GPs. The changing likelihood of being tested may 
also be due to the expanding availability and use of PCR testing in Australia. 
INTRODUCTION  
Pertussis, commonly known as whooping cough, is caused by the small, gram-negative 
coccobacillus, Bordetella pertussis. Classic whooping cough illness is characterised by 
intense paroxysmal coughing followed by an inspiratory “whoop”, especially in young 
children or those without prior immunity, followed by a protracted cough.2,3 It is now more 
widely understood that these characteristic symptoms are not always present during 
B. pertussis infection, and that individuals may only have symptoms similar to those of the 
common cold or a non-specific upper respiratory infection.3  
In recent years pertussis notifications have dramatically increased across Australia and in 
many other parts of the world.11,52,160,217 The rise has been seen in all Australian states 
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and territories, with the highest notification rates in children younger than 15 years of 
age.63 Although increased notifications may be due to a true increase in circulating 
B. pertussis, it is possible that the magnitude of the increase has been amplified by better 
recognition of disease and more frequent testing.218  
Historically, the diagnostic gold standard for pertussis laboratory testing was bacterial 
culture from nasopharyngeal secretions during the early phases of infection (weeks one 
and two), and serological testing was used as an alternate diagnostic method during the 
later phases of infection.3 However, even with ideal specimen collection, transport and 
handling, culture has low sensitivity and does not provide timely results. Although 
serological testing is more sensitive, both sensitivity and specificity may be lowered 
depending on the timing of specimen collection, and the patient’s infection and vaccination 
history.29 Polymerase chain reaction (PCR) testing has emerged as a key diagnostic 
method, and respiratory specimens are now commonly tested for pertussis using PCR in 
Australia and other countries.3,11,177 PCR testing provides more sensitive and rapid results 
than culture and serological testing. Also, PCR allows less invasive specimen collection, 
especially useful in younger age groups, in whom infection rates are high and serum 
collection may be challenging.2  
The key datasets used to monitor pertussis incidence and epidemiology in Australia – 
pertussis notifications, and pertussis-coded hospitalisations and deaths – are populated by 
positive test results from laboratories and, as such, are not independent of changes in 
testing practices. Without negative test results or other denominator data to assess 
changes in testing behaviour, it is difficult to distinguish changes in recorded disease 
incidence that are due to the effect of increased testing, from any true increase in disease.  
To better understand the role testing behaviour has on current pertussis epidemiology in 
Australia, we investigated pertussis testing trends in a stable set of general practice 
encounters. We hypothesised that the likelihood of pertussis testing, in a stable set of 
encounters that were most likely to result in a pertussis test request, has increased over 
time and that this may have led to amplification of laboratory-confirmed pertussis 
identification in Australia.  
METHODS 
We analysed data from the Bettering Evaluation and Care of Health (BEACH) program 
and the National Notifiable Diseases Surveillance System (NNDSS).  
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The BEACH program is a continuous cross-sectional national study that began collecting 
details of Australian general practice encounters in April 1998. Study methods for the 
BEACH program have been described elsewhere219 and are summarised in Appendix 1.  
Initially, all encounters for which a pertussis test (International Classification of Primary 
Care – Version 2 (ICPC2) Plus code = R33007 Test; pertussis) was ordered in the period 
April 2009 to March 2011 were identified and examined. During this period, 30 BEACH 
problems resulted in a pertussis test request at some time, and nine problems accounted 
for 90.9% of all pertussis test requests in the dataset. Four other problems, for which a 
pertussis test request was made at more than 1% of general practice management 
occasions of that problem, were added (Appendix 2). The 13 selected problems accounted 
for 92.3% of pertussis tests ordered between April 2009 and March 2011. These were 
labelled ‘pertussis-related problems’ (PRPs) and data for these problems at encounters 
recorded between April 2000 and March 2011 were extracted.  
BEACH data were grouped into two pre-epidemic periods (before the start of the national 
pertussis outbreak in 2008) and three epidemic years. During the pre-epidemic periods 
(April 2000 – March 2004 and April 2004 – March 2008), testing proportions were 
constant. For each pre-epidemic period and epidemic year, the proportion of PRPs with a 
pertussis test ordered and the proportion of BEACH problems that were PRPs were 
calculated. The proportions of PRPs with a pertussis test ordered were grouped into 
clinically meaningful age groups: 0 to 4 years, 5 to 9 years, 10 to 19 years, 20 to 39 years, 
40 to 59 years, and ≥60 years.  
The NNDSS collates notifications of confirmed and probable pertussis cases received by 
each State and Territory Health Department in Australia under appropriate public health 
legislation.175 Notified cases meet a pertussis case definition, which requires: laboratory 
definitive evidence; or laboratory suggestive and clinical evidence; or clinical and 
epidemiological evidence (Appendix 3).  
To match the BEACH years, all Australian pertussis notifications between April 2000 and 
March 2011 were extracted from the NNDSS database, including data on age and 
laboratory testing method. Pertussis notifications were aggregated by month and year, by 
age group, and by laboratory test method (serological, PCR, culture or unknown). 
Notifications that had more than one testing modality reported were classified into a single 
test category using the following hierarchy: culture, PCR, serological, unknown. A total of 
1,318 notifications were coded only as ‘antigen detection’, ‘histopathology’, ‘microscopy’, 
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‘not done’ or ‘other’ (epidemiologically-linked cases); these were excluded from the 
analysis as they accounted for only 0.9% of notifications over the study period. The rates 
of pertussis notifications per 100,000 population were then calculated for each 
pre-epidemic period and epidemic year. 
Temporal changes in the proportions of PRPs with a pertussis test ordered and the rates 
of pertussis notifications were assessed with a non-parametric test for trend over the 
whole study period and by calculating odds ratios with robust 95% confidence intervals. 
Correlation coefficients were calculated to determine the relationship between BEACH and 
NNDSS datasets. The BEACH analyses incorporated an adjustment for the cluster sample 
design. Initial BEACH analyses were performed using SAS version 9.1.3 (SAS Institute). 
Subsequent BEACH and NNDSS analyses were performed using Microsoft Excel and 
Stata version 11 (StataCorp). 
During the study period, the BEACH program had ethics approval from the University of 
Sydney Human Research Ethics Committee and the Australian Institute of Health and 
Welfare Ethics Committee. This particular study was approved by the University of 
Queensland Medical Research Ethics Committee. 
RESULTS 
The PRPs captured an average of 90.7% of all BEACH problems with a pertussis test 
ordered each year (range: 87.7%–92.7%) between April 2000 and March 2011 (Table 4). 
During the study period, PRPs as a proportion of all BEACH problems remained stable 
with an annual average of 8.0% (range: 7.7–8.7%). 
When the BEACH data were grouped into pre-epidemic periods and epidemic years, the 
proportion of PRPs with a pertussis test ordered increased about seven-fold, from 0.25% 
to 1.71%, when comparing April 2000 – March 2004 and April 2010 – March 2011 (Figure 
6; Table 5). This increase was highly correlated with NNDSS pertussis notification rates 
(correlation coefficient (r): 0.99), which increased about fivefold during the same period 
(Table 5). A highly significant trend was detected for changes in BEACH pertussis test 
requests (p<0.001) and NNDSS notification rates (p<0.001) from April 2000 to 
March 2011.  
In the age-specific analysis, there were significant increases in laboratory-confirmed 
pertussis notifications and the likelihood of pertussis test requests across all age groups 
during the study period (Table 5). When comparing April 2000 – March 2004 and 
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April 2010 – March 2011 pertussis testing rates, the largest increase was in 5 to 9 year old 
age group (odds ratio (OR): 11.6, 95% CI 4.2 – 36.7), followed by the 0 to 4 year old, 40 to 
59 year old, and ≥60 year old age groups. With the exception of the 5 to 9 year old group, 
the increase in pertussis testing exceeded notification changes in all age groups.   
Numbers of NNDSS pertussis notifications fluctuated over the study period (Figure 7). 
From 2008 onwards, there was a clear increase in the numbers of PCR-confirmed 
notifications. Before April 2008, most NNDSS notifications were confirmed by serological 
testing (66.0% to 80.7% of all notifications annually). The proportion of notifications 
confirmed by PCR increased from 16.3% in April 2000 – March 2004 to 65.3% in 
April 2010 – March 2011 (Table 4). The proportion of notifications confirmed by culture did 
not change, and accounted for an average of 2.0% of all notifications over the study 
period.   
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Table 4: PRPs as a proportion of all BEACH problems with a pertussis test ordered and as a proportion of all BEACH problems, 
and NNDSS PCR tests as a proportion of all NNDSS pertussis notifications, April 2000 to March 2011 
Period  
(April - March) 
PRPs as a proportion of all BEACH  
problems with a pertussis test ordered 
% (total no. pertussis tests) 
PRPs as a percentage of  
all BEACH problems  
% (total no. PRPs) 
NNDSS PCR tests as a proportion of all 
NNDSS pertussis notifications 
% (total no. of pertussis notifications) 
2000 – 2004 89.4% (141) 8.7% (51,396) 16.2% (16,997) 
2004 – 2008 92.1% (216) 7.9% (45,872) 11.0% (32,229) 
2008 – 2009 87.7% (114) 7.9% (12,551) 55.1% (18,059) 
2009 – 2010 92.7% (164) 7.8% (12,228) 56.8% (22,784) 
2010 – 2011 91.7% (216) 7.7% (11,557) 65.3% (33,661) 
 
CHAPTER 3 
 
47 
Figure 6: Proportions of BEACH PRPs with a pertussis test ordered, and NNDSS pertussis notification rates, April 2000 to 
March 2011 * 
 
* Data for 2000-2004 and 2004-2008 are averaged annual rates, and data for 2008-2009, 2009-2010, and 2010-2011 are annual rates.
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Table 5: Proportions of BEACH PRPs with a pertussis test ordered, and NNDSS pertussis notification rates per 100000 
population, by age group, April 2000 to March 2011 
Age 
group Dataset 
Period (April – March) 
Odds ratio 
(95% CI) ‡ 
Correlation 
coefficient (r) §  Pre-epidemic period * Epidemic year 
† 
2000-2004 2004-2008 2008-2009 2009-2010 2010-2011 
0 to 4 
years 
BEACH 0.16% 0.12% 0.48% 0.89% 1.31% 8.0 (3.9 - 17.2) 
0.89 
NNDSS 44.97 35.78 244.23 225.60 299.17 4.7 (4.3 - 5.2) 
5 to 9 
years 
BEACH 0.16% 0.22% 0.78% 2.61% 1.87% 11.6 (4.2 - 36.7) 
0.75 
NNDSS 29.68 17.55 202.17 260.06 507.62 14.2 (12.8 - 15.7) 
10 to 19 
years 
BEACH 0.36% 0.36% 1.27% 1.95% 2.05% 5.7 (2.8 - 11.4) 
0.88 
NNDSS 82.29 38.24 126.87 134.15 226.45 2.2 (2.1 - 2.3) 
20 to 39 
years 
BEACH 0.33% 0.54% 0.92% 1.10% 1.76% 5.4 (3.5 - 8.5) 
0.98 
NNDSS 22.58 34.51 64.41 84.42 105.60 2.8 (2.6 - 3.0) 
40 to 59 
years 
BEACH 0.25% 0.65% 1.05% 1.50% 2.09% 8.5 (5.2 - 14.0) 
0.99 
NNDSS 29.17 54.60 82.12 113.33 153.61 3.2 (3.0 - 3.4) 
≥60  
years 
BEACH 0.19% 0.41% 0.50% 0.54% 1.43% 7.6 (4.3 - 13.7) 
0.90 
NNDSS 16.12 50.15 76.57 103.49 142.84 5.6 (5.1 - 6.2) 
All ages 
BEACH 0.25% 0.43% 0.80% 1.24% 1.71% 7.0 (5.5 - 8.8) 
0.99 
NNDSS 33.73 42.31 88.86 108.56 158.42 3.2 (3.2 - 3.3) 
 
* NNDSS data are average notifications per 100000 population per year.  
† NNDSS data are notifications per 100000 population per year.  
‡ Comparison of 2000–2004 and 2010–2011 data.  
§ Correlation between BEACH and NNDSS data.
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Figure 7: NNDSS pertussis notifications by laboratory test method, April 2000 to March 2011 
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DISCUSSION 
Consistent with experience in other developed countries,6,11,190,220 we found that rates of 
pertussis notifications in Australia increased dramatically in recent years, from an average 
annual rate of 34 per 100,000 population in April 2000 – March 2004, to 158 per 100,000 
population in April 2010 – March 2011. Our results cast some light on the potential role 
that the increasing likelihood of a pertussis test request may have on this change.  
Using BEACH data, we found that individuals presenting to an Australian general 
practitioner between April 2010 and March 2011 were seven times more likely to have 
been tested for pertussis than 10 years earlier. This finding was within a set of general 
practice problems that remained stable as a proportion of all problems. This increased 
likelihood of pertussis testing, most evident in the epidemic years from April 2008 onwards, 
reached a maximum in the period April 2010 – March 2011, when pertussis tests were 
ordered in 1.71% of PRPs. A particular strength of our findings is that we used a data 
source that does not rely on laboratory testing, unlike most other datasets used to monitor 
pertussis in Australia and elsewhere.11,63,175,177  
The increased likelihood of testing in general practice coincided with an increasing 
proportion of NNDSS pertussis notifications being confirmed by PCR, from 16.3% between 
April 2000 and March 2004 to 65.3% between April 2010 and March 2011. A review of 
pertussis cases in New South Wales during the period 2008-2009 also showed a shift 
away from serological testing (the predominant method before 2008) to PCR testing from 
2008 onwards.177   
Pertussis notification rates and the likelihood of testing varied considerably across age 
groups. There was a dramatic increase in notification rates in 0-4 year olds and 5-9 year 
olds from the 2004-2008 pre-epidemic period to the 2008-2009 epidemic year, compared 
with a moderate increase in testing, which indicates that there probably was a true 
increase in disease for these groups during this period. It is possible that a real increase in 
0-4 year olds and 5-9 year olds early on prompted increased disease awareness among 
GPs, leading to widespread increases in testing across all ages. A positive feedback loop 
due to increased testing – leading to increased disease detection and awareness, leading 
to increased testing, and so on – may have been established. This interpretation is 
supported by the observation that although testing continued to increase from the 
epidemic year 2008-2009 to the epidemic year 2009-2010, there was little change in 
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notifications, suggesting an increase in testing during that period rather than an increase in 
disease. In the other groups, an increase in testing appeared to be responsible for 
magnified pertussis notifications. A study of pertussis resurgence in Toronto, Canada, also 
described this phenomenon and concluded that, although there had been true increase in 
local disease activity, the apparent size of the increase had been magnified by an increase 
in the use of pertussis testing and improvements in test sensitivity.11  
In Australia, public funding for pathology laboratories to use PCR to test specimens for 
pertussis (and other pathogens) commenced under the Medicare Benefits Schedule 
(MBS) in November 2005.187  This specific reimbursement for PCR testing (MBS item 
69494) – a Medicare Fee of $28.65 compared to $22.00 for culture (MBS item 69303) and 
$15.65 for serological testing (MBS item 69384)187 – may have been an incentive for 
laboratories across Australia to implement PCR testing more routinely. The laboratory 
profit margin for the different diagnostic methods is unknown, however as the processing 
costs for PCR decreased (particularly as PCR suites and reagents became less expensive 
over time) it may have become more profitable for laboratories to favour PCR testing. In 
addition, during the 2009 H1N1 pandemic, public funding was allocated for the purchase of 
laboratory equipment (notably PCR suites), but much of the funding was not received by 
laboratories until after the demand for pandemic influenza testing had subsided.188 New 
PCR capacity may have provided an increased opportunity for laboratories to conduct 
PCR testing for other pathogens, such as B. pertussis.  
Several factors may have contributed to an increase in disease during the study period. 
Pertussis laboratory testing methods have been documented to vary between children and 
adults. While, historically, culture would have been preferred to serological tests for the 
very young,195 children now are more likely to be tested using PCR, and adults are 
predominantly tested using serological tests.177 The variation in testing and notification 
rates across age groups may be due to differences in susceptibility and immunity.144 
Pertussis vaccination does not provide lifelong immunity against infection, with protection 
waning between booster doses.91 Waning immunity may partially explain differences in 
pertussis incidence between age groups, with older individuals having lower immunity due 
to longer periods since vaccination.144 Furthermore, there is evidence to suggest that 
whole cell pertussis vaccine formulations used in Australia and overseas before the late 
1990s provided longer lasting protection against B. pertussis infection than currently used 
acellular pertussis vaccines.80,95,220,221 It has also been suggested that immunity levels are 
waning faster in some age cohorts due to changes in vaccination schedules, such as the 
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removal of the 18 month booster dose.9 In addition, recent analysis of B. pertussis isolates 
collected in Australia between 2008 and 2010 indicates that there has been increasing 
circulation of vaccine-mismatched strains.222 Octavia et.al hypothesised this to be due to 
the selective pressure of vaccine-induced immunity in favour of strains carrying antigens 
that differ from those included in acellular vaccines.222 
While these or other factors may have led to a true increase in disease during the study 
period, our data suggest that increased testing, most likely due to expanding use of PCR 
during the study period, has almost certainly amplified the magnitude of notified pertussis 
activity in Australia. Similar amplification of pertussis notifications was also observed 
following the introduction and increased availability of serological testing in Australia,99 and 
has been reported during outbreaks with active case finding.193,223,224 Additionally, the 
increase in PCR testing might have led to identification of milder illness that would have 
otherwise gone undetected using older less sensitive laboratory methods. Availability of 
PCR would have also allowed laboratory confirmation of pertussis among those who would 
have previously been diagnosed clinically. As pertussis notifications do not capture 
disease severity, it is not possible to differentiate the impact of these drivers on clinician 
testing behaviour or the resultant increase in testing.  
Our findings have global implications, particularly for countries with high or expanding PCR 
availability. They highlight the critical importance of analysing changes in infectious 
diseases using a range of surveillance systems. By monitoring changes in laboratory 
testing and using surveillance datasets that do not rely on laboratory test results, it is 
possible to determine whether increases in notifications for diseases such as pertussis are 
due to a true increase in disease, and increase in testing, or a combination of both.  
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ABSTRACT  
Objective: To review the epidemiology of pertussis-related intensive care unit (ICU) 
admissions across Australia, over a 17-year period.  
Design: Retrospective descriptive study. 
Setting: Australian ICUs contributing data to the Australian and New Zealand Paediatric 
Intensive Care (ANZPIC) Registry. The number of contributing ICUs increased over the 
study period, from 8 specialist paediatric ICUs in 1997 to 8 specialist paediatric and 13 
general ICUs in 2013.  
Participants: All paediatric (<16 years) ICU admissions, coded as pertussis-related, 
between 01 January 1997 and 31 December 2013. 
Results: A total of 373 pertussis-coded ICU admissions were identified in the ANZPIC 
Registry over the study period. Of these cases, 52.8% occurred during the four years of 
the recent Australian epidemic (2009-2012). ICU admissions were most likely to occur in 
infants aged younger than 6 weeks (41.8%, n=156) and aged 6 weeks to 4 months 
(42.9%, n=160).  The median length of stay for pertussis-related ICU admissions was 
3.6 days, with 77.5% of cases staying in ICU for less than 7 days. Approximately half of all 
admissions (54.8%) required some form of respiratory support, with 32.7% requiring 
invasive respiratory support. Over the study period, 23 deaths were recorded (6.2% of 
pertussis-related ICU admissions), of which 20 (87.0%) were infants <4 months old.  
Conclusion: Pertussis-related ICU admissions occur primarily in infants too young to be 
fully protected from active immunisation. More needs to be done to protect these high risk 
infants, such as maternal immunisation.  
STRENGTHS AND LIMITATIONS OF THIS STUDY 
• We describe the epidemiology of Australian pertussis-related paediatric ICU 
admissions over a 17-year period. To date, research on severe pertussis infections in 
Australia has often been limited to a single state and specific epidemic period. 
• We used data collated in the Australian and New Zealand Paediatric Intensive Care 
(ANZPIC) Registry, which collects detailed paediatric intensive care patient episode 
information from contributing specialist paediatric ICUs (PICUs) as well as general 
ICUs (which admit mainly adult and some paediatric patients) across Australia and 
New Zealand. 
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• Any admissions to ICUs not contributing to the ANZPIC Registry would have been 
missed in our analysis, however the number of missing cases is expected to be low 
as all eight large specialist PICUs (which account for the vast majority of Australian 
paediatric ICU admissions) have participated in the ANZPIC Registry since 1997. 
• Our study used data from an existing database, and did not include a medical chart 
review or diagnostic testing results, it was therefore entirely reliant on the accuracy of 
existing coding.  
INTRODUCTION 
Pertussis, or whooping cough, is a highly infectious bacterial respiratory infection caused 
by the gram negative bacterium, Bordetella pertussis. It continues to be responsible for a 
high burden of disease across all age groups in Australia and overseas, despite long-term 
vaccination programs.61 
Infants younger than 6 months or age and unvaccinated individuals have the highest risk 
of severe infection and commonly require hospitalisation.225 As such, a primary goal of 
pertussis immunisation has been to minimise severe illness and deaths, particularly in 
infants.21 Despite concerted efforts, severe cases (requiring hospitalisation and/or ICU 
admission) and deaths continue to occur.60,177,194 
Pertussis vaccination was included on the first Australian National Immunisation Schedule 
in 1975, however pertussis vaccine has been used in Australia since 1942 in state-based 
programs.4  Vaccine formulations and scheduled doses have changed over time.4 
Currently, pertussis-containing vaccine doses are administered as a primary series at 
6 weeks, 4 months, and 6 months, followed by booster doses at 4 years and 15 years.21 In 
March 2015, re-introduction of the 18 month booster was recommended, with 
implementation of this dose commencing in October 2015. In addition to active 
immunisation, both cocoon and maternal vaccination have been nationally recommended 
to further reduce spread to young infants, with variable timing of introduction in different 
states.4 Cocoon vaccination requires immunisation of the close/regular contacts of a 
newborn infant to reduce the risk of exposure, while maternal vaccination (during the third 
trimester of pregnancy) allows transfer of antibodies to the foetus, and provides protection 
from the time of birth.21   
Research on severe pertussis infections – requiring hospitalisation or ICU admission, 
and/or causing death – in Australia has been limited, often restricted to a single state and 
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specific epidemic period.8,60,89,105,177,194 As such, there is little information available in the 
published literature about the epidemiology of severe pertussis infections at a national 
level over a time period that includes both epidemic and inter-epidemic periods, making 
historical and international comparisons difficult. The aim of this study was to describe 
Australian paediatric pertussis-related ICU admissions, using a large national dataset, over 
a 17-year period that incorporated epidemic and inter-epidemic periods.  
METHODS 
We conducted a retrospective descriptive study using data collated in the Australian and 
New Zealand Paediatric Intensive Care (ANZPIC) Registry between 1997 and 2013. The 
ANZPIC Registry was established in 1997 and collects paediatric intensive care patient 
episode information from contributing specialist paediatric ICUs (PICUs) as well as general 
ICUs (which admit mainly adult and some paediatric patients) across Australia and New 
Zealand.226 In 1997, eight PICUs from five Australian states (NSW, QLD, SA, VIC, WA) 
contributed data to the ANZPIC Registry.226 By 2013, one additional PICU (in TAS) and 
13 ICUs (representing all states/territories) were participating. The original eight PICUs, of 
which seven have contributed data continuously since commencement (eighth contributed 
in 1997-2008 only), accounted for an annual average of 93% of admissions recorded in 
the ANZPIC Registry between 1997 and 2013 (1997 value: 100%, 2013 value: 84%). 
Participating ICUs collect data in real-time either on a Microsoft Access database 
(Microsoft Corp, Redmond, WA, USA) supplied by the ANZPIC Registry or onto their local 
clinical information system (amended to include required ANZPIC Registry variables). Data 
are submitted to the centrally administered ANZPIC Registry electronically every six 
months.226  
A single record is created for each ICU admission and includes demographic data, 
physiological variables measured at the time of first face-to-face contact between the 
patient and ICU doctor, the ICU/hospital outcomes and length of stay, as well as the type 
and duration of respiratory support.226 Admissions are defined using ANZPIC 
Registry-specific diagnosis codes (standardised across all participating sites),227 and 
include ‘principal diagnosis’ (the diagnosis most directly responsible for the ICU 
admission), ‘underlying diagnosis’ (the principal underlying diagnosis contributing to the 
need for ICU admission), and up to seven ‘associated diagnoses’. Associated diagnoses 
are conditions additional to the principal and underlying reasons that contributed to the 
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ICU admission, and can include other syndromes, diseases, abnormalities or diagnoses 
identified on or during ICU admission. The treating clinician is responsible for selecting the 
appropriate diagnostic codes for each admission, and coding may be based on clinical 
symptoms, diagnostic test results, or a combination of both. Results of any diagnostic tests 
performed, including respiratory virus/bacteria detection, are not captured within the 
ANZPIC Registry. Immunisation history is also not collected.  
For this study, we extracted ANZPIC Registry data for all Australian paediatric (aged 0 to 
<16 years) ICU admissions between 01 January 1997 and 31 December 2013 with 
diagnosis codes of “470 – Pertussis Syndrome” or “720 – Pertussis” occurring in any of the 
diagnosis fields. The de-identified line-listed data extract included patient demographic 
variables (age, sex, ethnicity, state), as well as hospital and ICU admission details, 
including: admission/discharge dates, diagnoses (principal, underlying, and associated), 
discharge/outcome, and respiratory support variables (type and duration of respiratory 
support). Respiratory support was defined as any intervention to support respiratory 
function and includes both non-invasive and invasive methods. Some patients may have 
required combinations of both invasive and non-invasive support during their ICU 
admission. Non-invasive respiratory support includes continuous positive airway pressure, 
biphasic positive airway pressure, negative pressure ventilation, and high flow nasal 
cannula, while invasive respiratory support is mechanical ventilation delivered by 
endotracheal intubation or tracheostomy. 
Data were aggregated during analysis, including grouping by four-year periods  
(01 Jan 1997 – 31 Dec 2000; 01 Jan 2001 – 31 Dec 2004; 01 Jan 2005 – 31 Dec 2008;  
01 Jan 2009 – 31 Dec 2012) except for 2013 (presented as single year data: 01 Jan 2013 
– 31 Dec 2013), and chronological age. Admissions were classified as having co-detection 
if they had any other respiratory infection diagnosis code in any diagnostic field (in addition 
to one of the two pertussis codes). Cases were categorised as being premature 
(gestational age) if the code “826 – Prematurity (<37/40 & <12 months of age)” was 
included in any diagnosis field. Co-morbidity was defined by the inclusion of a diagnostic 
code (in any diagnosis field) for any congenital cardiovascular and/or respiratory 
abnormality, chronic lung disease, asthma, or cystic fibrosis.  
In Australia, pertussis is a nationally notifiable condition, and all cases that meet the case 
definition are required to be reported to the relevant State or Territory Health Department 
in accordance with public health legislation.175 We obtained national pertussis notification 
data between 01 January 1997 and 31 December 2013 for children aged <16 years from 
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the Australian Government Department of Health. Using mid-year Australian Bureau of 
Statistics population estimate data,206 we calculated the incidence of pertussis notifications 
(in children <1 year and children 1 to <16 years) per 100,000 age-specific population, and 
compared this with the incidence of pertussis-related ICU admissions per 100,000 
age-specific population. 
Stata version 12 (StataCorp, College Station, TX, USA) was used for data analysis. 
Descriptive statistics were calculated, including means, medians, and standard deviations 
(SD). The association between patient characteristics and outcomes was investigated 
using Student’s t-test (continuous variables) and risk ratios (categorical variables).  
Ethics approval for this study was obtained from the Children’s Health Services 
Queensland Human Research Ethics Committee.      
RESULTS  
Between 01 January 1997 and 31 December 2013, there were 373 pertussis-related ICU 
admissions of a total 113,197 all-cause ICU admissions recorded in the ANZPIC Registry 
(Table 6). Of pertussis-related ICU admissions, 83.9% (n=313) were admitted to PICUs 
and the remaining 16.1% (n=60) were admitted to general ICUs, however 78.3% (n=47) of 
the general ICU admissions occurred in 2009 to 2012. There were four years where the 
annual case number was higher than 40, all recorded between 2009 and 2012 
(2009 n=46; 2010 n=47; 2011 n=59; 2012 n=45), compared to a range of 4-26 cases per 
year in other years (Figure 8). 
Overall, the majority of cases (84.7%, n=316) were infants aged less than 4 months, of 
whom approximately half (n=156) were aged less than 6 weeks. The median age at time 
of admission was 48 days (range 0 days to 15.9 years). There were 28 cases (7.5%) aged 
over 12 months and the median age among these cases was 3.1 years (range 1.0 year to 
15.9 years).  
The incidence of ICU admissions and notifications in children <1 year and 1 to <16 years 
all followed a similar trend and all peaked in 2011 (Figure 9). The incidence of ICU 
admissions in children 1 to <16 years remained low (<0.2 per 100,000 population per year) 
over the study period. Notifications and ICU admissions in children aged <1 year were 
highly correlated (correlation coefficient = 0.96). 
The most common principal diagnoses coded for pertussis-related ICU admissions were 
‘pertussis syndrome’ (41.3%), ‘apnoea’ (12.6%), ‘pneumonia/pneumonitis’ (10.7%), 
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‘bronchiolitis’ (9.1%), and ‘respiratory failure’ (5.4%). The diagnosis codes used to identify 
pertussis-related admissions, 'pertussis syndrome' and 'pertussis', were both used in 
28.7% (n=107) of cases, and were used alone in 25.7% (n=96) and 45.6% (n=170) of 
cases, respectively. Although the relative proportions fluctuated from year to year, there 
was no preferential trend over time for using either one or both codes and they appeared 
to have been used interchangeably. Prematurity (defined as birth <37 weeks gestation) 
was coded in 45 cases (12.1%), however among cases aged <1 year, prematurity was not 
associated with significant differences in length of ICU stay (p=0.74), duration of both any 
or invasive respiratory support (p=0.92 and p=0.70, respectively), or death (p=0.23). 
Co-morbidities were coded in 6.7% (n=25) of cases, of which congenital cardiovascular 
conditions were present in 12 cases, chronic lung disease in six, and asthma in five. Three 
cases coded as having co-morbidities were also premature. No trend in the proportion of 
cases with co-morbidities was observed over the study period.  
Detection of another infectious pathogen (in addition to pertussis) was coded in 17.4% of 
cases (n=65), with the majority of co-detections due to respiratory syncytial virus 
(53.8%, n=35). Other co-detections included adenovirus (n=6), bacterial (n=6),  
“virus – other” (n=5), parainfluenzae (n=4), two Haemophilus influenzae type B 
co-infections (in 2000, 2002) and two influenza co-infections (2007, 2008). Although the 
proportion of cases with co-detection fluctuated from year to year, the lowest occurring in 
2013 (5.6%, n=1) and highest in 2008 (37.5%, n=6), there was no clear increasing or 
decreasing trend over the study period. Cases in whom co-detection of infection occurred 
were significantly older than those with pertussis only (mean(standard deviation (SD)):  
1.3 (3.3) years vs 0.4 (1.5) years, respectively, mean difference(MD): 0.9 years, 95%CI: 
0.4 to 1.4 years, p=0.0008) and the proportion of cases with co-detection increased with 
increasing age (<6 weeks: 12.2%, 6 weeks to <4 months: 18.1%, 4 months to <6 months: 
21.4%, 6 months to <1 year: 26.7%, >1 year: 35.7%). Compared with cases of pertussis 
only (n=308), those with co-infection (n=65) had a significantly longer mean duration of 
invasive ventilation (mean(SD): 2.0 (6.6) days vs 7.4 (26.3) days, respectively, MD: 
5.4 days, 95%CI: 2.1 to 8.7 days, p=0.0016) and had a longer mean length of ICU stay 
(mean(SD): 5.4 (9.1) days vs 10.1 (26.0) days, respectively, MD: 4.7 days, 95%CI: 1.1 to 
8.4 days, p=0.01). There was no significant difference in deaths between cases of 
pertussis only and cases with co-detection (6.5% vs 4.6%, respectively, RR=0.7, 95%CI: 
0.2 to 2.3, p=0.57).   
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Cases stayed in the ICU for a median of 3.6 days (range 0 to 209 days), with 77.5% of 
cases staying in ICU for less than 7 days, 15.5% staying between 7 and <14 days, 6.4% of 
cases staying between 14 to <50 days, and only two cases (0.5%) staying in ICU for 
longer than 50 days (120 and 209 days). No significant difference was observed between 
age at admission (<4 months vs ≥4 months) and length of ICU stay (mean(SD): 5.8 (9.3) 
days vs 8.6 (27.4) days, respectively, MD: 2.8 days, 95%CI: -1.1 to 6.7 days, p=0.16).  
Of all pertussis cases, approximately half (54.8%) required some form of respiratory 
support during their ICU admission, with 35.7% needing respiratory support during the first 
hour (Table 6). Invasive respiratory support was required by 32.7% of pertussis ICU 
admissions and the median time of invasive support was 2.7 days (range 0.1 hours to 
196.1 days). Children aged ≥4 months appeared to have a longer point estimate for mean 
duration of invasive respiratory support compared to infants aged <4 months, however this 
finding was not statistically significant (mean(SD): 5.3 (27.6) days vs 2.5 (7.1) days, 
respectively, MD: 2.8 days, 95%CI: -0.8 to 6.3 days, p=0.13). 
Over the study period there were 23 recorded deaths among pertussis related ICU 
admissions: 12 in infants aged <6 weeks (of n=156, 7.7%), 8 in infants aged between 
6 weeks and <4 months (of n=160, 5.0%), and the remaining 3 were in children aged over 
12 months (of n=57, 5.3%). Infants aged <6 weeks did not have a significantly higher risk 
of death compared to older infants and children (relative risk: 1.5, 95%CI: 0.7 to 3.4, 
p=0.3). The highest number of deaths occurred between 2001 and 2004 (n=8) and 
between 2009 and 2012 (n=7). As a percentage of all pertussis-related ICU admissions, 
deaths were highest in 1997-2000 (10.6%, n=5) and 2001-2004 (12.1%, n=8). No deaths 
were recorded during 2013.      
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Figure 8: Pertussis-related paediatric ICU admissions, Australia, 1997-2013, by year and age at admission 
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Figure 9: Annual cumulative incidence of pertussis-related admissions to contributing ANZPIC Registry ICUs* and national 
pertussis notifications by age group (<1 year and 1 to <16 years), per 100,000 child-years, Australia, 1997-2013 
 
* The pertussis-related ANZPIC Registry ICU admissions presented in this figure will be an under-representation of all pertussis-related paediatric ICU admissions in 
Australia due to non-participation of some ICUs that admit children, including adult ICUs that do not report their data to the ANZPIC Registry. 
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Table 6: Demographics and admission characteristics of pertussis-related ICU admissions, 1997-2013 
Year of admission 1997-2000 2001-2004 2005-2008 2009-2012 2013* Total 
Number of participating ICUs+ 7 to 9 9 to 14 13 to 19 19 to 20 21 7 to 21 
Pertussis-related admissions 
Number (percent of total pertussis admissions) 47 (12.6%) 66 (17.7%) 45 (12.1%) 197 (52.8%) 18 (4.8%) 373 (100%) 
Pertussis-related ICU admissions per 1000 all-cause ICU admissions 
(total all-cause ICU admissions) 
2.2 
(21,263) 
2.7 
(24,636) 
1.6 
(27,385) 
6.4 
(30,954) 
1.9 
(9,232) 
3.3 
(113,197) 
Sex 
Male - Number (percent) 25 (54.3%) 41 (62.1%) 22 (48.9%) 85 (43.2%) 9 (50.0%) 182 (48.9%) 
Ethnicity 
Aboriginal and Torres Strait Islander peoples – Number with ethnicity 
recorded (percent) 
5 of 46 (10.9%) 8 of 66 (12.1%) 1 of 16 (6.3%) 4 of 45 (8.9%) 0 of 10 (0%) 18 of 183 (9.8%) 
Age       
Aged <6 weeks 24 (51.1%) 25 (38.9%) 12 (26.7%) 87 (44.2%) 8 (44.4%) 156 (41.8%) 
Aged 6 weeks to <4 months 21 (44.7%) 35 (53.0%) 23 (51.1%) 72 (36.6%) 9 (50.0%) 160 (42.9%) 
Aged 4 to <6 months 2 (4.3%) 0 (0%) 2 (4.4%) 10 (5.1%) 0 (0%) 14 (3.8%) 
Aged 6 months to <1 year 0 (0%) 2 (3.0%) 4 (8.9%) 9 (4.6%) 0 (0%) 15 (4.0%) 
Aged ≥1 year 0 (0%) 4 (6.1%) 4 (8.9%) 19 (9.6%) 1 (5.6%) 28 (7.5%) 
Median age (range) 42 days (17d - 152d) 
49 days 
(19d - 14.6y) 
62 days 
(4d - 15.2y) 
48 days 
(0d - 15.9y) 
45.5 days 
(23d - 8.4y) 
48 days 
(0d - 15.9y) 
Case state/territory of residence ‡ 
Number (percent of total pertussis-related admissions); total all-cause ICU admissions     
Australian Capital Territory 0 (0.0%); ND 0 (0.0%); 110 0 (0.0%); 112 1 (0.5%); 121 0 (0.0%); 26 1 (0.3%); 369 
New South Wales 16 (34.0%); 5,896 11 (17.5%); 7,217 25 (56.8%); 8,037 70 (35.9%); 9,274 4 (22.2%); 2,526 126 (34.3%); 32,950 
Northern Territory 1 (2.1%); ND 3 (4.8%); ND 2 (4.5%); 222 1 (0.5%); 243 0 (0.0%); 83 7 (1.9%); 548 
Queensland 10 (21.3%); 5,201 11 (17.5%); 5,697 5 (11.4%); 7,177 43 (22.1%); 7,984 2 (11.1%); 2,843 71 (19.3%); 28,902 
South Australia 3 (6.4%); 2,345 12 (19.0%); 2,265 4 (9.1%); 2,170 9  (4.6%); 2,179 0 (0.0%); 555 28 (7.6%); 9,514 
Tasmania 0 (0.0%); 62 0 (0.0%); 163 0 (0.0%); 338 9 (4.6%); 853 2 (11.1%); 215 11 (3.0%); 1,631 
Victoria 3 (6.4%); 4,953 16 (25.4%); 5,699 5 (11.4%); 6,272 50 (25.6%); 7,228 10 (55.6%); 2,185 84 (22.9%); 26,337 
Western Australia 14 (29.8%); 2,806 10 (15.9%); 3,212 3 6.8%); 3,057 12 (6.2%); 3,072 0 (0.0%); 799 39 (10.6%); 12,946 
Patients with co-morbidities 
Number (percent) 5 (10.6%) 7 (10.6%) 9 (20.0%) 30 (15.2%) 1 (5.6%) 52 (13.9%) 
Patients with infectious agent co-detection 
Number (percent) 5 (10.6%) 7 (10.6%) 14 (31.1%) 38 (19.3%) 1 (5.6%) 65 (17.4%) 
Length of ICU stay 
Median (range) 
3.6 days  
(<1d-35d) 
3.7 days  
(<1d-36d) 
3.6 days  
(<1d-50d) 
3.4 days  
(<1d-209d) 
6.1 days  
(1d-11d) 
3.6 days  
(<1d-209d) 
Respiratory support required during 1st hour of ICU admission § ** 
Number (percent) 16 (34.0%) 22 (33.8%) 21 (46.7%) 67 (34.0%) 7 (38.9%) 133 (35.7%) 
Respiratory support required during ICU admission § ** 
Number (percent) 20 (46.5%) 27 (46.5%) 19 (63.3%) 107 (58.5%) 9 (50.0%) 182 (54.8%) 
Invasive respiratory support required during ICU admission ++ 
Number (percent) 17 (36.2%) 27 (40.9%) 23 (51.1%) 52 (26.4%) 3 (16.7%) 122 (32.7%) 
Length of invasive respiratory support ++ 
Median (range) 
3.5 days 
(5.0h - 31.4d) 
4.9 days 
(8.6h - 32.2d) 
4.8 days 
(0.8h - 40d) 
3.8 days 
(1.5h - 208.6d) 
6.6 days 
(2.0d - 7.6d) 
4.5 days 
(0.8h - 208.6d) 
Deaths 
Number (percent) 5 (10.6%) 8 (12.1%) 3 (6.7%) 7 (3.1%) 0 (0%) 23 (6.2%) 
* Single year of data. 
+ Number of participating ICUs increased during the time period. 
ǂ 3 ICU admissions had no residential state recorded and 3 were classified as residing overseas.  
§ Respiratory support is defined as any intervention to support respiratory function and includes both non-invasive and invasive methods. Some patients may have required combinations of both invasive and non-invasive support during their 
ICU admission. Non-invasive respiratory support includes: continuous positive airway pressure, biphasic positive airway pressure, negative pressure ventilation, and high flow nasal cannula. 
** Respiratory support during 1st hour data were missing for 161 cases. Respiratory data during admission data were missing for 41 cases. 
++ Invasive respiratory support is mechanical ventilation delivered by endotracheal intubation or tracheostomy.   
ND = No ICUs contributing to ANZPIC Registry during this time period (cases treated interstate). h = hours, d = days, y = years 
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DISCUSSION 
There were 373 paediatric patients with pertussis-related ICU admissions between 1997 
and 2013. Of these, 84.7% occurred in infants younger than four months or age and 
approximately half (53%) occurred during the most recent Australian pertussis epidemic 
period (2009-2012). While it is reassuring that few ICU admissions occurred among age 
groups that can be protected by vaccination (≥4 months old), a finding that is consistent 
with the existing literature on pertussis-related hospitalisations,8,60,89,105,194 our results 
indicate that more needs to be done to protect young infants (<4 months) who are most 
vulnerable to severe disease. Interestingly, the proportion of admissions requiring invasive 
ventilation increased over the study period while the proportion of deaths declined from a 
peak in 1997-2000 (likely associated with an outbreak of pertussis in 1996-1997228), 
however it is unclear whether this reflects better clinical management of pertussis or a 
change in disease severity.  In the literature, there are very limited data available about 
pertussis ICU admissions, which are an important indicator of disease severity, falling 
between hospitalisation and death. While our findings were mostly consistent with the 
studies we could identify focusing on pertussis ICU admissions,229-234 only one of these 
studies was Australian (based in Melbourne)231 and only one was published in the last five 
years,233 limiting our ability to draw comparisons.  
Infants younger than six months of age are at highest risk for morbidity and mortality 
associated with pertussis infection. Australian vaccination schedules have been altered 
over time in an effort to better target protection to this group.21 From 2009, in response to 
increasing pertussis notifications across Australia, cocoon vaccination strategies were 
implemented at state level between 2009-2012 (program timing and eligibility varied by 
state).4 Cocoon strategies aim to provide newborn infants with protection by vaccinating 
those around them in order to reduce the risk of transmission. We did not observe a 
decrease in ICU admissions among infants aged <6 months related to the cocoon 
programs, however these programs coincided with record high pertussis incidence which 
may have masked any program-related decline in cases.  
Additionally, in early 2011, the National Immunisation Schedule was updated with a 
recommendation to provide the first pertussis vaccine dose at six weeks of age (rather 
than at two months) in an effort to provide infants with some level of protection as early as 
possible. By late 2011, five states (NSW, ACT, TAS, QLD and VIC) had about 50-70% of 
infants vaccinated with their first dose between six to less than eight weeks of age, while 
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other states were slower to implement the change (SA 40%, NT 30%, WA 20%).235 A 
study by Foxwell and colleagues estimated that this schedule change would be associated 
with an annual reduction of up to 10% of pertussis-related hospitalisations.104 Our data did 
not show any decline in pertussis ICU admissions among 6-8 week old infants following 
the recommendation, although two years (2012-2013) may not be a long enough 
timeframe to see the full impact of this change and again any reductions in incidence may 
have been masked by the pertussis epidemic. 
Immunisation status is not part of the set of data recorded for paediatric ICU admissions in 
the ANZPIC Registry. While it would be ideal to have the immunisation status of cases, it 
is worth noting only 11.5% of admissions occurred in age groups eligible to have been fully 
vaccinated (≥6 months). The remainder of admissions were infants either too young to 
have received any vaccine doses (<6 weeks, 41.8%) or who may have been partially 
vaccinated with one or two doses (6 weeks to <6 months, 46.7%). In two Australian 
studies where immunisation status was known, pertussis-related hospitalisations primarily 
occurred in infants too young to have been vaccinated or older infants that had not been 
appropriately vaccinated for their age.60,194 
While the ANZPIC Registry contains national data and has provided an indication of 
pertussis-related ICU admissions across Australia, it may have underestimated the 
number of ICU admissions for a number of reasons. Firstly, any admissions to ICUs not 
contributing in the ANZPIC Registry would have been missed in our analysis. In the earlier 
years of this study, fewer general ICUs contributed paediatric data to the ANZPIC 
Registry, however the number of missing cases is expected to be low as all eight large 
specialist PICUs (which account for the vast majority of Australian paediatric ICU 
admissions) have participated in the ANZPIC Registry since 1997.226 Secondly, as our 
study used data from an existing database, and did not include a medical chart review or 
diagnostic testing results, we were entirely reliant on the accuracy of existing ANZPIC 
Registry coding, which has not previously been validated. We will have missed any real 
cases not coded as ‘pertussis’ or ‘pertussis syndrome’, as well as prematurity and any 
co-detections or co-morbidities not listed in one of the diagnosis fields. Inclusion of 
diagnosis codes is highly dependent on clinician awareness, diagnostic testing, and 
perceived importance of the illness.193 Improvements in diagnostic testing, with the 
widespread use of PCR from 2007 onwards205 as well as high media coverage (for 
example, following infant deaths and during the 2009-2012 epidemic), may have 
influenced pertussis testing and awareness among clinicians primarily during the latter part 
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of our study period. Additionally, the likelihood of identifying co-infecting viruses is likely to 
have improved over time with increasing use of multiplex PCR. Unfortunately it is not 
possible to measure the impact of diagnostic testing changes on awareness and/or ICU 
admission coding as diagnostic data are not available in the ANZPIC Registry. We 
hypothesise however, that it is more likely that pertussis cases and co-detections were 
missed earlier in the study period, although the number missing cannot be quantified.  
Even with protective vaccination strategies such as cocooning, and moving the first dose 
to six weeks of age, infants particularly younger than four months of age continue to be at 
risk. Both maternal and neonatal vaccination are being assessed as possible 
solutions.61,103,129,130,236,237 Assessment of the Public Health England maternal pertussis 
vaccination program (which commenced in 2012) found vaccine effectiveness of 91% 
against confirmed pertussis in infants younger than two months of age.129,130 A birth dose 
of pertussis vaccine has also been shown to induce protective antibody responses, and 
therefore protection against pertussis, prior to six months of age, but so far study sizes 
have been small.236 In March 2015, the Australian Government recommended a pertussis 
booster for pregnant women during the third trimester of pregnancy, and all 
states/territories now have locally funded programs. The results from the United Kingdom 
are encouraging, in regards to coverage as well as safety and effectiveness,129-132 
however there are significant barriers to uptake in Australia that will need to be overcome 
to achieve similar outcomes.238 Evaluations of these programs and their impact on 
pertussis epidemiology will be an important area of research over the coming years. 
CONCLUSION 
Severe pertussis cases, requiring ICU admission, continue to occur primarily in infants too 
young to be fully protected from active immunisation. More needs to be done to protect 
these high risk infants. In Australia, implementation of maternal immunisation programs in 
all states and territories offers the hope of much better disease control in this age group. If 
coverage is high, we can expect reductions in pertussis-related ICU admissions and 
mortalities in infants.  
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Chapter 5 – Diagnostic testing of Australian influenza and 
pertussis-related paediatric intensive care unit admissions, 
1997-2013 
 
 
This chapter is presented as a submitted original research manuscript: 
Kaczmarek MC, Schlebusch S, Ware RS, McEniery JA, Coulthard MG, Lambert SB. 
Diagnostic testing of Australian influenza and pertussis-related pediatric intensive care unit 
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ABSTRACT  
Objective: Severe respiratory infections make up a large proportion of Australian paediatric 
intensive care unit (ICU) admissions each year. Identification of the causative pathogen is 
important and informs clinical management. We investigated the use of polymerase chain 
reaction (PCR) in the ICU-setting by reviewing the diagnostic testing of pertussis and 
influenza-related paediatric ICU admissions.  
Design: Retrospective cohort study using data collated by the Australian and New Zealand 
Paediatric Intensive Care (ANZPIC) Registry. 
Setting: Two paediatric and three general intensive care units in Queensland, Australia, 
participating in the ANZPIC Registry. 
Patients: All paediatric patients admitted to a participating ICU for influenza or 
pertussis-related illness between 01 January 1997 and 31 December 2013. 
Intervention: None. 
Measurements and Main Results: There were 177 influenza-related ICU admissions and 
78 pertussis-related ICU admissions. Overall, 157 (88.7%) influenza-related admissions 
had an influenza-specific diagnostic test conducted, of which 129 (82.2%) had a PCR test 
requested. Patients that were tested for influenza using non-PCR tests all occurred prior to 
2007. An influenza-positive result was recorded for 130 (82.8%) of the tested 
influenza-related ICU admissions – 73.4% of all ICU admitted influenza-related cases. 
Among pertussis-related admissions, 63 (80.8%) had a pertussis-specific diagnostic test 
ordered, of which 60 (95.2%) were tested using PCR. A pertussis-positive result was 
recorded for 53 (85.5%) of those tested, and 67.9% of all ICU admitted pertussis-related 
admissions.  
Conclusion: PCR has become the preferred diagnostic method to test influenza and 
pertussis-related paediatric ICU admissions, largely replacing the use of other methods. 
This finding mirrors trends observed across other healthcare settings, but appears to have 
occurred earlier among paediatric ICU admissions, aligning with the clinical imperative to 
identify the aetiology of severe respiratory illness. The move to PCR testing, allowing more 
sensitive and rapid diagnosis, has likely improved clinical management of severe pertussis 
and influenza infections among children.  
INTRODUCTION 
Severe respiratory infections among infants and young children make up approximately 
one-third of all Australian paediatric intensive care unit (ICU) admissions each year.226,239 
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Respiratory infections can be caused by a range of viral and bacterial pathogens, and 
given that infants and children can manifest a broad array of non-specific symptoms, 
identifying the aetiology based on clinical presentation alone is difficult.240-242 Identification 
of the causative pathogen is important, particularly in severe cases, in order to inform 
clinical management and infection control protocols.242 As such, infants and children that 
are hospitalised or admitted to ICU are likely to be tested for a broad range of respiratory 
pathogens.243  
In the last decade, polymerase chain reaction (PCR) has largely replaced traditional 
diagnostic methods, such as culture and immunofluorescence, for routine testing of 
respiratory samples.244,245 In Australia, influenza and pertussis are notifiable conditions 
under public health legislation, and all cases that meet the case definitions must be 
reported to State and Territory Health Departments.175,203 Influenza and pertussis are the 
two most common vaccine preventable notifiable diseases in Australia,21,245 and the 
increasing use of PCR has, in part, been linked to better case recognition and 
magnification of the number of notifications.205,245  
The incidence of paediatric influenza and pertussis-related ICU admissions has increased 
in recent years.246,247 It is unclear whether PCR use has influenced this trend, as 
diagnostic testing changes in the ICU setting have not previously been investigated. To 
date, only two Australian studies have reported diagnostic testing among pertussis and 
influenza hospitalizations, however these studies focused on overall laboratory findings 
and not changes to laboratory methods over time.240,248 The aim of this study was to 
investigate the use of PCR in the ICU setting by reviewing the diagnostic testing of 
influenza and pertussis-related paediatric ICU admissions in Queensland, Australia, over a 
17-year period.  
METHODS 
We conducted a retrospective cohort study using data collated by the Australian and New 
Zealand Paediatric Intensive Care (ANZPIC) Registry on ICU admissions between 
01 January 1997 and 31 December 2013. Data relating to the admission of paediatric 
patients aged 0 to 16 years was extracted. The ANZPIC Registry collects paediatric 
intensive care patient episode information from contributing specialist paediatric ICUs 
(PICUs) as well as general ICUs (which admit mainly adult and some paediatric patients) 
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across Australia and New Zealand.226 Ethics approval for this study was obtained from the 
Children’s Health Services Queensland Human Research Ethics Committee.  
For this study, only admissions to contributing ICUs located in the state of Queensland 
were extracted. Data from two hospitals with PICUs located in Brisbane (‘PICU A’ and 
‘PICU B’), and three hospitals with general ICUs located in regional areas (‘General ICU 
A’, ‘General ICU B’, and ‘General ICU C’) were used. The two Brisbane-based PICUs, 
PICU A and PICU B, contributed data for the full study period (1997-2013), during which 
time they treated 10,264 and 13,158 all-cause admissions, respectively. The other three 
ICUs began contributing admission data for 0 to 16 year olds to the ANZPIC Registry later: 
General ICU A from 2002 (1,028 all-cause paediatric ICU admissions 2002-2013), General 
ICU B from 2006 (331 all-cause paediatric ICU admissions 2006-2013), and General 
ICU C from 2009 (97 all-cause paediatric ICU admissions 2009-2013). Participating ICUs 
collect data in real-time and a single record is created for each ICU admission.226 
Admissions are defined using ANZPIC Registry-specific standardised diagnosis codes,227 
and include ‘principal diagnosis’ (the diagnosis most directly responsible for the ICU 
admission), ‘underlying diagnosis’ (the principal underlying diagnosis contributing to the 
need for ICU admission), and up to seven ‘associated diagnoses’. Associated diagnoses 
are conditions additional to the principal and underlying reasons that contributed to the 
ICU admission, and can include other syndromes, diseases, abnormalities, or diagnoses 
identified on or during ICU admission. For this study, we extracted ANZPIC Registry data 
for all Queensland paediatric ICU admissions with diagnosis codes of ‘470 – Pertussis 
Syndrome’, ‘720 – Pertussis’, or ‘715 – Influenza Virus’ occurring in any of the diagnosis 
fields. The line-listed data extract included patient demographic variables and ICU 
admission details, as well as a hospital identification number. Immunisation history, 
medications/treatments prescribed during admission, and laboratory data used to support 
the diagnosis coding are not collected in the ANZPIC Registry.  
Using the hospital identification number for each ICU admission, we searched for any 
respiratory diagnostic tests occurring from 14 days prior to ICU admission to seven days 
after ICU discharge (based on specimen collection date) in appropriate pathology 
databases (the Pathology Queensland Laboratory Information System, Auslab, and/or the 
Mater Pathology Laboratory Information System, Kestral). Where tests were found, we 
recorded the sample date, sample method (e.g. nasopharyngeal swab or aspirate), 
diagnostic method (e.g. PCR, serology, culture, antigen detection), and result for each 
test. Diagnostic method was coded as ‘PCR’ (≥1 test done, where at least one 
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PCR-based), ‘non-PCR’ (≥1 test done, none were PCR-based), or ‘no tests found’. The 
test results were coded as ‘influenza positive only’, ‘pertussis positive only’, ‘other 
respiratory pathogen positive’ (influenza and pertussis negative), ‘influenza and other 
respiratory pathogen positive’, ‘pertussis and other respiratory pathogen positive’, or 
‘negative’ (no respiratory pathogen identified). Co-detection was defined as a respiratory 
test positive for another respiratory pathogen, in addition to a positive influenza/pertussis 
result. Where another respiratory pathogen was detected, the organism was recorded. 
Descriptive statistics, including frequency, proportion, median, or range, were calculated 
as appropriate. Comparisons between groups were calculated using the non-parametric 
Mann-Whitney U-test. We calculated the proportion of ICU admissions tested using any 
testing modality, as well as the proportion of admissions with a matching positive 
diagnostic test result. All analyses were conducted using Stata statistical software v.12 
(StataCorp, College Station, TX, USA). 
RESULTS 
Between 1997 and 2013, there were 177 influenza-related paediatric ICU admissions and 
78 pertussis-related paediatric ICU admissions in the five participating ICUs (Table 7). 
Admissions predominantly occurred in Brisbane (PICU A, 52.2%; n=133; PICU B, 40.4%; 
n=103). Children with influenza-related admissions were older than children with 
pertussis-related admissions (median age: 2 years vs. 51 days, respectively, p<0.001), 
and had a shorter median length of ICU stay (2.6 days vs. 4.3 days, respectively, 
p=0.049). A total of 16 deaths were recorded, of which eight (4.5%) were influenza-related 
admissions and eight (10.3%) were pertussis-related admissions.  
Influenza-related admissions were highest in 2011 (n=26 admissions), and 119 (67.2%) 
occurred between 2007 and 2013 (Figure 10). Overall, 157 (88.7%) influenza-related 
admissions had an influenza-specific diagnostic test conducted. An influenza positive 
result was recorded for 130 (82.8%) of those tested and 73.4% of all influenza coded 
admissions (Table 8). Prior to 2007, 28 influenza-related admissions were tested using 
non-PCR diagnostic tests, which included one or a combination of: immunofluorescence, 
antigen detection, culture, or serology. From 2008 onwards, all tested influenza-related 
admissions included a PCR test (10 admissions had a combination of PCR with antigen 
detection, serology, or immunofluorescence). 
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Pertussis-related admissions between 2009 and 2012 accounted for 61.5% (n=48) of total 
pertussis-related admissions during the study period (Figure 11). Among pertussis-related 
admissions, 62 (79.5%) had a pertussis-specific diagnostic test ordered. A 
pertussis-positive result was recorded for 53 (85.5%) of those tested and for 68.0% of all 
pertussis coded admissions. Only three pertussis-related ICU admissions, all prior to 2002, 
were tested using a non-PCR diagnostic method (immunofluorescence) and all three had 
negative results. For the remaining 59 tested pertussis-related admissions, 42 had PCR 
testing only, and the remaining 17 had serology, antigen detection, culture, or 
immunofluorescence testing used in combination with PCR.  
Co-detection of another respiratory pathogen was identified in 13.6% (n=24) 
influenza-related admissions and 19.2% (n=15) pertussis-related admissions (Table 7). 
Additionally, there were 18 ICU admissions coded as influenza-related, that tested 
negative for influenza but positive for one or more respiratory pathogens, including: 
parainfluenza (type 2 n=1, type 3 n=9), rhinovirus (n=5), Haemophilus influenzae type B 
(HiB, n=2), and respiratory syncytial virus (RSV, n=2). Among these 18 admissions, only 
one HiB-positive admission and both RSV-positive admissions had relevant HiB or 
RSV-specific ICU diagnosis codes in addition to the influenza ICU diagnosis code. There 
were no influenza/pertussis co-detections. 
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Table 7: Influenza and pertussis admissions, 1997-2013, Queensland Australia 
 Influenza Pertussis 
Total admissions 177 78 
Admitting ICU [n (%)] 
PICU A 
PICU B 
General ICU A 
General ICU B 
General ICU C 
 
105 (59.3%) 
63 (35.6%) 
8 (4.5%) 
1 (0.6%) 
0 (0.0%) 
 
28 (35.9%) 
40 (51.3%) 
2 (2.6%) 
4 (5.1%) 
4 (5.1%) 
Sex - Male [n (%)] 97 (54.8%) 42 (53.8%) 
Age [median (range)] 2.0 years  (16 days – 14.6 years) 
51 days  
(16 days – 8.4 years) 
Length of stay [median (range)] 2.6 days (0.2 - 57.7) 
4.3 days 
(0.3 - 120.3) 
Deaths [n (%)] 8 (4.5%) 8 (10.3%) 
Tested for coded illness [n (%)] 157 (88.7%) 62 (79.5%) 
Number of coded respiratory pathogen specific tests performed per admission  
[median (range)] a 2 (1 - 10) 3 (1 - 21) 
Admissions with relevant positive laboratory test [n (%)] 130 (73.4%) 53 (67.9%) 
Co-detection of other respiratory pathogen [n (%)] 
RSV-positive [n] 
adenovirus-positive [n] 
rhinovirus-positive [n] 
parainfluenza type 3-positive [n] 
human metapneumovirus-positive [n] 
24 (13.6%) 
12 b 
6 b 
3 c 
2 
3 c 
15 (19.2%) 
4 
3 
6 d 
2 d 
1 
a where one or more diagnostic tests conducted. Cases with no test identified were excluded. 
b one case positive for influenza, RSV, and adenovirus – counted in both rows. 
c two cases positive of influenza, rhinovirus, and human metapneumovirus – counted in both rows. 
d one case positive for pertussis, rhinovirus, and parainfluenza type 3 – counted in both rows. 
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Table 8: Influenza and pertussis paediatric ICU admissions by test type and result, 1997-2013, Queensland Australia 
 Influenza Pertussis 
Year 
Total 
admissions 
n 
Non-PCR 
test/s  
n 
(% positive)a 
PCR test/s 
n 
(% positive)a 
Not 
tested 
n 
Tested 
% b 
Test 
positive 
% a 
Total 
admissions 
n 
Non-PCR 
test/s 
n 
(% positive)a 
PCR test/s 
n 
(% positive)a 
Not 
tested 
n 
Tested 
% b 
Test 
positive 
% a 
1997 4 0 (-) 0 (-) 4 0.0 0.0 3 0 (-) 0 (-) 3 0.0 0.0 
1998 5 1 (100.0) 0 (-) 4 20.0 20.0 5 1 (0.0) 0 (-) 4 20.0 0.0 
1999 5 2 (50.0) 0 (-) 3 40.0 20.0 1 1 (0.0) 0 (-) 0 100.0 0.0 
2000 5 5 (100.0) 0 (-) 0 100.0 100.0 1 0 (-) 1 (100.0) 0 100.0 100.0 
2001 6 6 (100.0) 0 (-) 0 100.0 100.0 5 1 (0.0) 4 (75.0) 0 100.0 60.0 
2002 11 9 (100.0) 2 (100.0) 0 100.0 100.0 5 0 (-) 4 (100.0) 1 80.0 80.0 
2003 5 1 (0.0) 3 (100.0) 1 80.0 60.0 1 0 (-) 0 (-) 1 100.0 0.0 
2004 4 0 (-) 4 (100.0) 0 100.0 100.0 1 0 (-) 1 (100.0) 0 100.0 100.0 
2005 5 1 (100.0) 2 (100.0) 2 60.0 60.0 3 0 (-) 2 (100.0) 1 66.7 66.7 
2006 8 1 (100.0) 7 (85.7) 0 100.0 87.5 0 - - - - - 
2007 17 2 (100.0) 15 (100.0) 0 100.0 100.0 0 - - - - - 
2008 18 0 (-) 18 (83.3) 0 100.0 83.3 3 0 (-) 3 (100.0) 0 100.0 100.0 
2009 15 0 (-) 14 (78.6) 1 93.3 73.3 12 0 (-) 8 (87.5) 4 66.7 58.3 
2010 6 0 (-) 5 (80.0) 1 83.3 66.7 9 0 (-) 9 (100.0) 0 100.0 100.0 
2011 26 0 (-) 25 (72.0) 1 96.2 69.2 11 0 (-) 11 (81.8) 0 100.0 81.8 
2012 22 0 (-) 19 (84.2) 3 86.4 72.7 16 0 (-) 14 (85.7) 2 87.5 75.0 
2013 15 0 (-) 15 (53.3) 0 100.0 53.3 2 0 (-) 2 (100.0) 0 100.0 100.0 
Total 177 28 (92.9) 129 (80.6) 20 88.7 73.4 78 3 (0.0) 59 (89.8) 16 79.5 67.9 
a percentage of admissions positive for specific pathogen  
b percentage of admissions tested for specific pathogen using any testing modality 
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Figure 10: Influenza admissions by test method and year, 1997-2013, Queensland Australia 
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Figure 11: Pertussis admissions by test method and year, 1997-2013, Queensland Australia 
CHAPTER 5 
 
81 
DISCUSSION 
The vast majority of paediatric ICU admissions for influenza and pertussis in Queensland, 
Australia, between 1997 and 2013 had at least one pathogen-specific diagnostic test 
conducted. This aligns with the clinical imperative to identify the aetiology of severe 
respiratory illness. For both illnesses, PCR largely replaced other methods over time and 
became the predominant diagnostic test, mirroring what has previously been observed 
among national influenza and pertussis notifications.245 Interestingly, the move to PCR 
testing appears to have occurred earlier among ICU admissions (from approximately 
2001-2002 onwards) than among notifications (from approximately 2007 onwards).245 As 
PCR testing was still relatively novel in 2001-2002, its use at that time will have been 
expensive, limited to larger laboratories, and run as one-off diagnostic tests rather than 
mass routine testing.249 As such, the use of PCR for pertussis testing may have been 
limited to severely ill children, including those admitted to an ICU, within a large tertiary 
hospital. However as the benefits of PCR compared to culture became increasingly 
accepted over time, including much higher sensitivity (94% vs. ~15%, respectively) and 
faster results,172 clinicians are likely to have made it their preferred choice for of diagnostic 
test when treating infants with severe respiratory infections when it was available. It was 
only in 2005 that public funding commenced, under the Australian Government-funded 
Medicare Benefits Schedule, for laboratories to test clinical specimens using PCR.187 
Additionally, during the 2009 H1N1 influenza pandemic, public funding was allocated to 
laboratories to purchase equipment (notably PCR suites) to enhance capacity.188 While 
funding facilitated the expansion of PCR availability, the development and use of 
large-scale, multiplex PCR assays has allowed testing and identification of a broader 
range of respiratory pathogens, including the detection of co-infections.250-254  
The ANZPIC Registry is a well-established dataset, and has been collating data from 
participating ICUs since 1997. A particular strength of the Registry is that it captures data 
from the two large dedicated PICUs in Queensland, as well as from three smaller general 
ICUs in more regional areas, therefore capturing the vast majority of paediatric ICU 
admissions across the state and allowing generalisability of the findings. Additionally, by 
keeping data definitions largely consistent over a 17-year period, it provides the 
opportunity to analyse trends over a long time frame. A limitation of the ANZPIC Registry 
is that laboratory results are not captured, and the diagnosis codes have not previously 
been validated. We found that for approximately 70% of influenza and pertussis-related 
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ICU admissions there was a corresponding relevant positive influenza or pertussis 
laboratory test result. When limited to only those admissions that had a diagnostic test 
conducted (89% of influenza-related admissions, 80% of pertussis-related admissions), 
approximately 85% had a matching positive result. We were unable to locate any previous 
studies, specifically validating coding for ICU admissions, with which to compare our 
results. Our findings however, were consistent with a previous study which validated the 
ICD-10 coding of influenza and pertussis hospitalisations in Western Australia.248    
Our results likely represent minimum values as we were reliant on the accuracy and 
completeness of the databases that we used. We included all ICU admissions coded as 
influenza and pertussis, however any admissions that were due to, but not coded as, 
‘influenza’ or ‘pertussis’ would have been missed. Similarly, as we did not include a 
medical chart review, we will have included any admissions incorrectly coded as influenza 
or pertussis-related. For example, we identified 18 influenza-coded ICU admissions that 
were negative for influenza, but positive for other respiratory pathogens. While these ICU 
admissions may have been diagnosed as influenza-related based on clinical symptoms, it 
is possible that there was some misclassification with the ANZPIC Registry coding, 
particularly influenza coded admissions where parainfluenza or Haemophilus influenzae 
type B were laboratory diagnosed. Additionally, although we conducted an extensive 
search of the pathology datasets, any diagnostic tests not contained within the database, 
for example, tests conducted by a private pathology provider or outside of our search 
criteria (between 14 days before ICU admission through to 7 days after ICU discharge), 
will have been missed. However, it is reassuring that the majority of ICU admissions had at 
least one diagnostic test identified.  
The move to PCR testing in the ICU setting, allowing more sensitive and rapid diagnosis 
compared to earlier diagnostic methods, has likely improved clinical management of 
severe pertussis and influenza infections among children and possibly led to a reduction in 
healthcare costs. Viruses are more commonly responsible for acute respiratory infections 
in children, therefore rapid detection of a viral pathogen in a general practice setting would 
allow a clinician to withhold antibiotic treatment. In the ICU setting however, viral detection 
would not tend to alter antibiotic use due to concerns of secondary bacterial infection.244,255 
On the other hand, rapidly detecting a bacterial pathogen may aid a clinician’s decision to 
prescribe and/or continue particular antibiotics earlier, in both settings.255 The fast 
turn-around of PCR results compared to culture, may have also contributed to a reduction 
in healthcare costs. Where a diagnosis is quickly obtained, additional (often unnecessary) 
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laboratory tests and/or diagnostic imaging may be avoided.244,256,257 Furthermore, rapid 
diagnosis in a hospital/ICU setting would allow appropriate infection control measures to 
be enforced, limiting the likelihood of nosocomial infections.244,257 
In conclusion, PCR has become the preferred diagnostic method in influenza and 
pertussis-related ICU admissions. This finding mirrors the trends observed more broadly 
across other healthcare settings.  
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Chapter 6 – Pertussis Seasonality Evident in Polymerase Chain 
Reaction and Serological Testing Data, Queensland, Australia 
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ABSTRACT   
We investigated the seasonality of pertussis in Queensland, Australia, between 2008 and 
2011 using notification and laboratory data. Polymerase chain reaction and serology 
testing data demonstrate that in the vaccine era, pertussis remains a seasonal illness, with 
annual peaks in summer months, and that the seasonality of notification data is masked by 
testing trends.  
INTRODUCTION 
Many infectious diseases show clear seasonal patterns in both temperate and tropical 
climates, and seasonality has been well documented particularly for viral respiratory 
infections.258 The seasonality of pertussis is less clear and it is the cause of debate. There 
is some suggestion that there is no clear seasonality;259 however, in the pre-vaccine era it 
was widely accepted that pertussis peaked in the spring and summer months.260  
During the last five years, a pertussis resurgence has been observed in a number of 
countries.261 Australia experienced a pertussis epidemic between 2008 and 2011, which 
was larger and more prolonged than previous outbreaks in the vaccine era.64  
With this study, we sought to better understand the seasonality of pertussis in 
Queensland, an Australian state with a subtropical and tropical climate, using available 
laboratory and notification data during the recent pertussis epidemic.  
METHODS 
Two Queensland-based diagnostic laboratory providers, Pathology Queensland (PQ) and 
Sullivan Nicolaides Pathology (SNP), provided data on pertussis diagnostic tests (PCR 
and serology) performed between 01 January 2008 and 31 December 2011. PQ is the 
only public laboratory, providing pathology services to all Queensland public (government 
funded) hospitals, while SNP is a large, privately run, diagnostic laboratory, primarily 
servicing community-based patients. The two laboratories were responsible for 36% of 
pertussis notifications during the study period (range 34-38% per year), with one other 
private laboratory largely responsible for the remainder of notifications (57%). Data from 
PQ & SNP were combined for this analysis.  
In Queensland, pertussis is a notifiable condition, and all cases meeting the case definition 
must be reported to the State Health Department in accordance with the Public Health Act 
2005. Over the study period, a confirmed pertussis case required one of the following 
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conditions to be met: definitive laboratory evidence (isolation of Bordetella pertussis by 
culture or detection by a nucleic acid amplification test, such as a PCR assay); suggestive 
laboratory evidence (single high serum IgA titre to B. pertussis antigen or evidence of 
seroconversion) and clinical evidence (coughing illness lasting ≥2 weeks or one of: 
coughing paroxysms, inspiratory whoop or post-tussive vomiting); or clinical evidence and 
epidemiological evidence (contact between two people involving plausible mode of 
transmission when one of them is likely to be infectious and the other has an illness onset 
within 6-20 days after contact).175 Data for all pertussis notifications reported to 
Queensland Health between 01 January 2008 and 31 December 2011 were obtained. 
Both datasets were analysed by month based on specimen registration date (laboratory 
data) and onset date (notifications). Using the laboratory data, we calculated the 
proportion of tests positive for pertussis, and compared these with counts of Queensland 
pertussis notification data.  
The University of Queensland, School of Population Health Human Research Ethics 
Committee approved this study. 
RESULTS 
A total of 48,578 pertussis PCR tests and 79,505 pertussis serology tests were conducted 
by the two laboratories between 01 January 2008 and 31 December 2011, of which 
4,574 (9.4%) and 10,465 (13.2%) were positive, respectively.  
Peak serology tests occurred annually in winter or spring months: September 2008 
(n=1,514), July 2009 (n=2,090), September 2010 (n=3,425), and August 2011 (n=2,372). 
PCR tests could be categorized into two low-testing periods, January 2008-January 2009 
(mean=322 per month) and January 2010-October 2010 (mean=406 per month), and two 
high-testing periods, February 2009-December 2009 (mean=918 per month) and 
November 2010-December 2011 (mean=2,160 per month). During the high-testing 
periods, PCR tests peaked in July 2009 (n=1,495), March 2011 (n=2,662) and August 
2011 (n=3,025). When PCR and serology tests were aggregated, three primary peaks 
were observed in July 2009, November 2010 and August 2011. 
The proportion of tests positive was highest between October and February (inclusive) 
compared to between March and September (PCR monthly mean=13.5% vs 6.9%; 
serology monthly mean=15.5% vs 11.7%, respectively). The proportion of tests positive 
peaked primarily in summer months between 15-18% for PCR and 16-22% for serology, 
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decreasing between autumn and early spring (March to September) to lows of 
approximately 5% for PCR and 10% for serology (Figure 12). 
There were a total of 25,688 pertussis notifications in Queensland between  
01 January 2008 and 31 December 2011. Seasonal trends were less evident in 
Queensland notification data, with a broad peak observed between May 2008 and January 
2009, followed by distinct peaks in November 2010 and November 2011 (Figure 12). 
Notification data and the number of total positive tests were highly correlated (correlation 
coefficient=0.97). 
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Figure 12: Proportion of tests positive for pertussis (by test type) and pertussis notifications, 01 January 2008 – 
31 December 2011, Queensland Australia  
 
0
250
500
750
1000
1250
0%
5%
10%
15%
20%
25%
Ja
n
Fe
b
M
ar Ap
r
M
ay Ju
n Ju
l
Au
g
Se
p
O
ct
N
ov De
c
Ja
n
Fe
b
M
ar Ap
r
M
ay Ju
n Ju
l
Au
g
Se
p
O
ct
N
ov De
c
Ja
n
Fe
b
M
ar Ap
r
M
ay Ju
n Ju
l
Au
g
Se
p
O
ct
N
ov De
c
Ja
n
Fe
b
M
ar Ap
r
M
ay Ju
n Ju
l
Au
g
Se
p
O
ct
N
ov De
c
2008 2009 2010 2011
To
ta
l n
um
be
r o
f n
ot
ifi
ca
tio
ns
 
Pe
rc
en
t o
f t
es
ts
 p
os
iti
ve
 fo
r p
er
tu
ss
is
Month and Year
Total notifications PCR % positive Serology % positive
CHAPTER 6 
 
90 
DISCUSSION 
Using diagnostic test positivity, we have demonstrated that pertussis remains a seasonal 
illness in Queensland with activity peaking in summer each year between 2008 and 2011. 
Seasonality was less evident in notification data, with peaks in notifications largely 
coinciding with the periods during which most diagnostic tests were conducted.  
Seasonality trends among notifications have been masked by retrospective testing using 
serology as well as the increasing use of PCR. We observed that while the proportion of 
positive serology tests peaked in summer months, it remained high inter-seasonally. The 
use of serology for retrospective diagnosis of pertussis, and the lower specificity serology 
results compared with PCR,95 will have broadened the seasonal peak of pertussis within 
notification data. PCR testing for pertussis has been increasing in Australia since 2007, 
becoming the preferred diagnostic test especially for infants and children, because of its 
high sensitivity, ease of sample collection, quick turn-around, and ability to test one sample 
for multiple respiratory pathogens.82 Of the three testing peaks we observed, two occurred 
during periods of very high influenza activity (winter 2009 and winter 2011).64 Laboratories 
that routinely run PCR tests for a group of respiratory pathogens (that include influenza 
and pertussis) are likely to inadvertently diagnose pertussis in cases suspected to have a 
viral respiratory infection (such as influenza). Therefore, PCR testing for multiple 
respiratory pathogens has likely resulted in amplified pertussis case detection and 
increased notifications during periods of high viral activity.  
Testing is ultimately influenced by clinician behaviour as well as the clinical presentation 
and/or behaviour of patients. Clinician behaviour can be modified by increased awareness 
or the establishment of a positive feedback loop (where positive results prompt more 
testing, leading to more positive results and so on).193 Conversely, negative test results 
during the decline of an epidemic could create a negative feedback loop, however the 
improved awareness gained throughout the epidemic could possibly lead clinicians to 
continue testing clinically compatible cases leading to a slower deceleration of the 
epidemic. Substantial media attention during the pertussis epidemic, likely prompted 
changes in both patient and clinician behaviour,213 which may have led to differential 
testing over the study period and/or the establishment of a positive feedback loop. 
Differential testing may introduce spectrum bias, however the direction and size of this 
bias, if any, cannot be determined using the data available.   
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Similar to notifications, the proportion of tests positive can be influenced by increased 
testing. We observed the highest proportion positive in summer months, when there is the 
least testing, and the inverse in winter months, when testing is highest. While this may 
have been influenced by variation in tests conducted, in contrast to changes in the 
circulation of B. pertussis, PCR testing continued to be used during summer months. As 
PCR is used to diagnose acute infection, and other respiratory infections are less common 
during summer,258 this supports the notion that pertussis has summer seasonality.  
Our findings are likely to be representative of Queensland patients and demonstrate 
pertussis seasonality in a sub-tropical climate. The two laboratories service all areas of 
Queensland (including regional areas), accounted for a stable proportion of total 
notifications each year, and included community-based and hospitalised patients (mild 
through to severe clinical presentations). Both SNP and the other private pathology 
provider are present and accessible to patients across Queensland, making it unlikely in 
our view that data from only one laboratory would not be representative of the testing 
spectrum of both laboratories. Additionally, the high correlation between notifications and 
positive test results suggests the laboratory data included accurately reflect state-wide 
pertussis cases. Queensland’s population primarily lives along the state’s south-east 
coast, in a sub-tropical climate. As such, we believe our results demonstrate pertussis 
seasonality in a sub-tropical climate. Seasonality in other climates warrants further 
investigation.  
Pertussis seasonality in notification data is masked by the use of serology and general 
increases in PCR testing. By calculating the proportion of tests positive, we were able to 
clearly demonstrate the summer seasonality of pertussis in Queensland, Australia.  
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Chapter 7 – Discussion and Conclusion 
Summary of findings 
In the last decade, pertussis incidence has increased in Australia and overseas, with large 
sustained epidemics occurring most notably in developed countries, despite well-
established immunisation programs with high coverage.6,177,262 Australia had a pertussis 
epidemic between 2009 and 2012 that peaked at 38,602 notified cases during 2011.1 This 
prompted concerns about the effectiveness of pertussis control strategies and programs.8 
There have been a number of hypotheses put forward internationally to explain this 
resurgence of pertussis; one was that it was the result of increased diagnostic testing.6 
In Australia, disease incidence in the community is predominantly monitored using 
notification data. In Chapter 2, I was able to demonstrate that from 2005, PCR quickly 
replaced all other laboratory methods for pertussis diagnosis, although serology is still 
used for a proportion of adolescents and adults. Historically, culture was used for pertussis 
diagnosis, however a positive culture result is less likely among immunised individuals and 
the likelihood of a positive culture decreases with increasing age.2,10 Therefore, culture-
positive notification had maximum sensitivity for young, unimmunised patients. In addition 
to demonstrating a shift to PCR-based notifications, we also observed that the age 
distribution of notifications changed over time, with increasing incidence among children 
and adolescents. I hypothesised that because PCR allowed better case detection among 
these age groups, notifications were beginning to reflect the true burden of pertussis in 
Australia.   
As notification data can be biased by changes in testing practices, awareness, and 
definitions,6,11,12 in Chapter 3, I investigated changes in the likelihood of pertussis testing in 
the general practice setting over time. I was able to demonstrate, within a stable set of GP 
encounters for respiratory illness, that the odds of being tested for pertussis among GP 
presentations in 2010-2011 were seven times higher than ten years earlier. The increase 
in odds of testing was most dramatic among children aged 5-9 years (OR: 11.6). These 
findings can, at least in part, explain an increase in notifications as an artefact of increased 
testing.  
In Chapter 4 I reviewed the epidemiology of severe pertussis cases, with the hypothesis 
that ICU admissions would be less biased by changes in diagnostic testing. I observed that 
there was an increase in the number of pertussis-related ICU admissions in Australia 
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during the recent epidemic period (2009-2012). I subsequently reviewed the diagnostic 
testing of pertussis-related paediatric ICU admissions in Queensland (Chapter 5). I found 
that in the ICU setting there was also a clear shift towards PCR testing. An increase in 
testing was not observed in the ICU setting, however this was not surprising given the 
clinical imperative to determine the aetiology of a severe respiratory infection. Among 
infants younger than one year of age, pertussis-related ICU admissions and pertussis 
notifications were highly correlated, even during the epidemic period.  
Finally, in Chapter 6 I demonstrated the impact that diagnostic testing changes have had 
on one aspect of pertussis epidemiology – seasonality. It was once accepted that pertussis 
had seasonal peaks, however these peaks are no longer able to be observed in 
notification data. By calculating the number of tests positive per month as a proportion of 
diagnostic tests conducted, I was able to show that in Queensland, pertussis remains a 
seasonal illness, with peaks in summer each year. This highlights that changes in 
underlying testing patterns have broader effects on our understanding of pertussis 
epidemiology.  
What this research adds 
National surveillance systems in developed countries like Australia, the United States, 
United Kingdom, and Canada, were among the first to detect the increasing incidence of 
pertussis.6,11,177 All of these surveillance systems are highly reliant on laboratory 
confirmation of cases. Investigating the underlying testing patterns in the Australian setting 
has demonstrated increasing use of PCR-based diagnostic testing, as well as increasing 
likelihood of being tested for pertussis in the GP setting, coinciding with increasing 
pertussis notifications. From these findings we can surmise that the observed pertussis 
resurgence can be attributed, at least in part, to changes in diagnostic testing. Other 
studies investigating the role of diagnostic testing in the United States and Canada have 
come to equivalent conclusions.6,11,263 Although not as dramatic, a similar increase in 
Australian pertussis notifications was observed in the 1990s after serology testing became 
widely available, allowing testing and diagnosis of older children, adolescents, and 
adults.264,265 In contrast, the review of pertussis-related ICU admissions indicated that the 
resurgence of pertussis was not merely an artefact of testing, as there was an increase in 
admissions during the epidemic period (2009-2012) that did not coincide with diagnostic 
testing changes (the move to PCR-based testing occurred earlier in the ICU setting). 
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When considered in combination, the findings of this Thesis support the hypothesis that 
while there was a real increase in pertussis activity between 2009 and 2012, the increased 
likelihood of testing and shift to PCR-based diagnosis are likely to have magnified the 
recorded incidence of pertussis in Australia, particularly in laboratory-confirmed 
notifications. 
Earlier diagnostic methods were rarely used among older children and adolescents, due to 
the low likelihood of positive results in previously vaccinated individuals.2 PCR filled this 
gap by allowing testing across the whole age spectrum, and was pivotal in detecting the 
increase in pertussis activity among children five to 14 years or age. This led other 
researchers to investigate the possible causes of increased pertussis activity particularly 
among this age group.  
In Australia from 1997, scheduled pertussis booster doses were replaced with acellular 
vaccines, and from 1999, acellular vaccines replaced all doses on the National 
Immunisation Schedule.4 The age group with the highest notification rates during the 
recent pertussis epidemics in Australia and the United States were children approximately 
five to 14 years of age, which corresponded with the first birth cohorts to have received 
acellular pertussis vaccine for all scheduled doses.80,92 In a retrospective review of 
laboratory-confirmed pertussis cases in California, United States, Witt et al. (2012) 
identified rapidly waning immunity following acellular pertussis vaccines, with risk of 
infection increasing with time since last vaccine dose.80 The US immunisation schedule is 
similar to that currently used in Australia, with doses at 2, 4, and 6 months, 15-18 months, 
4-6 years, and 11-12 years.77,266 Subsequent studies in the United States demonstrated 
that protection against pertussis waned during the five to six years after the fifth vaccine 
dose (administered at four to six years of age).55 In a retrospective study of pertussis 
notifications in Queensland, Australia, among children born in 1998 who may have had 
scheduled vaccine doses as all acellular, all whole cell, or a mixture of both, 
Sheridan et al. (2012) demonstrated that infant priming with whole cell vaccine was 
associated with a lower risk of subsequent pertussis, compared to priming with acellular 
vaccine.95 A similar but larger study conducted in the US had consistent findings, and 
concluded that immunisation using acellular vaccine for all doses was less durable than a 
schedule that contained at least one dose of whole cell vaccine.267   
During the recent epidemic an increased incidence of pertussis was observed among 
Australian children three to five years of age. In contrast, no increases were observed in 
this age group in the United States, where the immunisation schedule includes a booster 
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dose at 15-18 months.89 The Australian National Immunisation Schedule, since its 
establishment in 1975, did include a booster dose at 18 months, however this was 
removed in 2003 based on evidence from Italy suggesting that immunity following a three 
dose primary series, without a booster at 18 months, persisted until six years of age.4,77,268 
With a booster dose already scheduled for children at four to five years of age, and 
increasing notifications among adolescents, the decision was made to simultaneously 
remove the 18 month booster and introduce an adolescent booster (a cost neutral 
change), with the prospect of improved pertussis control.4,21 However the increasing 
notifications among young children during the recent epidemic prompted questions about 
the duration of immunity following the three dose primary series. An Australian 
retrospective case-control study found VE against laboratory-confirmed pertussis waned 
rapidly during the first few years after a three dose acellular vaccine primary series.89 
Among infants and children who had received three vaccine doses, VE was estimated at 
83.5% for children six to less than 12 months of age, but had declined to 59.2% for 
children three to four years of age.89 With strengthening evidence of the limited durability 
of acellular vaccines, the 18 month booster dose was returned to the Australian National 
Immunisation Schedule in 2015.4 This extra childhood dose will likely curb the increase in 
notified disease in pre-school age children, however adverse events associated with this 
dose will need to be closely monitored as the 18 month booster was associated with 
increased risk of local reactions prior to its removal from the schedule.269 The better longer 
term solution is for vaccines with more durable protection. 
Together, rapidly waning immunity following the introduction of acellular vaccines, and in 
Australia, the removal of the 18 month booster dose, go some way to explaining the 
dramatic increase in cases among children and adolescents. The move to PCR-based 
testing and increasing likelihood of testing, allowed diagnosis of pertussis across all age 
groups, detection of the acellular waning immunity problem, and magnification of overall 
pertussis activity.  
Strengths 
There are many advantages to using existing well-established datasets for retrospective 
studies, such as those used for the studies in this Thesis. Each of the data sources has 
been in existence for over a decade; for example, pertussis notifications have been 
captured in the NNDSS since 1991, the ANZPIC Registry has been collating data since 
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1997, and BEACH has been collecting data since 1998.1,239,270 Using these datasets 
allowed analysis of data over long periods of time, making it possible to detect changing 
trends. Additionally, our findings are generalisable internationally, particularly to countries 
with similar surveillance systems that are based primarily on laboratory confirmation of 
cases, such as the United States, Canada, United Kingdom, and some countries in 
Europe.11,192,263 For instance, in the United States and Canada, where pertussis diagnosis 
has also become predominantly PCR-based, similar increases in pertussis incidence and 
changes to pertussis epidemiology have been reported.6,11,263 
While pertussis notification data have been routinely analysed and reported, analysis of 
severe pertussis infections (requiring hospitalisation or ICU admission, and/or causing 
death) in Australia has often been restricted to a single State and specific epidemic 
period.8,60,89,105,177,194,271 There is, therefore, limited published literature about the 
epidemiology of severe pertussis infections at a national level over a time period that 
includes both epidemic and inter-epidemic periods, thereby making historical and 
international comparisons difficult. Additionally, understanding the epidemiology of severe 
pertussis is vital for appropriate pertussis immunisation and control programs which are, in 
the absence of vaccines that eliminate disease, primarily aimed at reducing severe 
illness.21 Through a novel analysis of ANZPIC Registry data, the study presented in 
Chapter 5 addressed these gaps by reviewing pertussis-related ICU admissions nationally 
over a 17-year period.   
A particular strength of the BEACH data analysis (Chapter 4) was that it demonstrated an 
increase in testing using a dataset that was independent of laboratory detection biases. In 
Australia and overseas, surveillance systems used to monitor pertussis activity are 
primarily based on reporting laboratory-confirmed cases.1,11,131,175,177,192,272 Although 
diagnosis using laboratory methods is likely to be more accurate than diagnosis based on 
clinical symptoms alone,38,273,274 changes in underlying diagnostic testing trends or 
laboratory case definitions can bias observed incidence.11 While it was possible to 
demonstrate the shift to PCR-based diagnosis in pertussis notification data, without 
capturing the total number of tests requested or calculating the proportion of tests positive, 
an increase in testing cannot be ascertained using notification data alone. The analysis of 
BEACH data provided confirmation that there had been an increase in the likelihood of 
pertussis diagnostic testing in general practice (primary care) across Australia.  
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Limitations 
Each study included in this Thesis has provided a minimum estimate, due to data 
collection limitations leading to missing cases or tests. The NNDSS, a passive surveillance 
system, primarily captures laboratory-confirmed pertussis cases.175 As a passive system, it 
requires individuals to self-present to healthcare providers, who need to order a diagnostic 
test (or notify based on clinical symptoms), and the laboratory is then required to notify all 
positive test results. An unknown number of cases are missed at each step in this 
progression, resulting in the number of notifications being an underestimate of true 
pertussis activity.38,195 This weakness would have been more pronounced earlier during 
the study period, when fewer individuals were tested and there was more emphasis on 
clinical diagnosis (which is difficult due to the wide spectrum of clinical presentation).38,273 
Additionally, due to the deficiencies of testing methods like culture, false negative results 
may have been common prior to the widespread use of PCR.11 Although false positives 
can also occur, they would be infrequent and mostly due to laboratory procedural issues.12 
However PCR also allows detection of transient carriage of B. pertussis as well as 
asymptomatic infections, and this is likely to have magnified the number of notifications 
following its widespread use. The NNDSS is almost entirely reliant on the notification of 
laboratory positive results and does not capture whether a clinically compatible illness was 
absent or present at the time of swab collection. Without clinical details, it is difficult to 
determine whether a PCR positive result reflects a ‘true’ pertussis case (i.e. with 
compatible illness), and it is not possible to quantify the proportion of ‘true’ pertussis cases 
among notifications. 
Changing awareness of pertussis over time will have influenced all of the datasets used to 
some extent. Across Australia there was extensive media coverage of rising pertussis 
incidence, deaths in very young infants, and following official announcements, such as 
those publicising the commencement of cocoon immunisation programs.4,275,276 Increased 
awareness can influence the behaviour of patients, prompting earlier presentation, and 
healthcare providers, prompting diagnostic testing.193 A positive feedback loop may have 
been established, where increased pertussis positive results, either due to increased use 
of more sensitive diagnostic methods like PCR or increased pertussis activity, led to 
increased pertussis testing by healthcare providers and increased awareness, leading to 
more testing, and so on.11,277 In the hospital and ICU setting, selection and use of 
diagnostic codes is highly dependent on clinician awareness, diagnostic testing, and 
perceived importance of the illness.193,248,277 For example, in the ANZPIC Registry, any 
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real pertussis cases not coded as ‘pertussis’ or ‘pertussis syndrome’ in one of the 
diagnosis fields will have been missed. A recent Australian study found that 31% of 
hospitalisations, notified as pertussis according to the national case definition (majority 
likely to be laboratory confirmed cases), did not have a diagnosis of pertussis included in 
the hospital discharge coding.278 Earlier studies have also identified that hospitalised 
pertussis cases have been misclassified as caused by other respiratory pathogens,38,195 
however these studies were before the widespread use of PCR. As awareness and testing 
were lower earlier in the study periods, it is probable that more cases were missed earlier 
rather than later.  
The datasets chosen, although largely representative of the Australian, or Queensland, 
populations, may have been biased towards metropolitan rather than rural populations. In 
rural and remote settings, patients can have very limited access to GPs, hospitals 
(especially dedicated paediatric ICUs), and diagnostic testing,279 which are required to be 
captured in one or more of the datasets used. Although our findings can be generalised to 
metropolitan areas of Australia, the generalisability to rural/remote areas of Australia may 
be limited. It is worth noting, however, that the population of Australia defined as living in 
‘remote’ or ‘very remote’ areas is only approximately 3%.280  
By using existing datasets, without performing data linkage or medical chart reviews, these 
studies were entirely reliant on the accuracy of the datasets. Laboratory data were 
expected to be highly accurate, given the need for laboratory accreditation and the use of 
quality assurance mechanisms. Notification of laboratory positive results would also be 
largely accurate, although transcription/human errors would be possible where manual 
data entry of notifications is required. Both the BEACH program and ANZPIC Registry 
have been internally validated, and both adopt methods that maximise the reliability of 
coding and data entry.226,239,270,281 The datasets chosen are believed to be highly accurate, 
consequently the likelihood of inaccuracies contributing to bias is low.  
Implications 
Clinical  
Serology (in the 1990s) and more recently PCR, improved our understanding of the signs 
and symptoms of pertussis. B. pertussis infection was once characterised by ‘typical’ 
symptoms and thought to be a childhood illness, however as a result of improvements in 
laboratory diagnosis, the clinical spectrum is now understood to include asymptomatic or 
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mild infections through to severe manifestations, across all age groups.13 Improved 
diagnostic testing has also increased the recognition and clinical implications of respiratory 
co-infections.13,229,282,283 
In the clinical setting, rapid identification of the aetiology of respiratory infections would 
improve patient management and possibly lead to a reduction in healthcare costs.257,284,285 
While viruses are more commonly responsible for acute respiratory infections in children 
and adults, it is difficult to distinguish the clinical history and symptoms of viral infections 
from bacterial infections.286 In the general practice setting, timely detection of a viral 
pathogen using PCR, would allow a clinician to withhold antibiotic treatment when 
appropriate. With growing global concerns about antimicrobial resistance, there is 
increasing pressure to limit the use of unnecessary antibiotics.286-288 Where B. pertussis 
was identified as the pathogen, appropriate antibiotics could be prescribed, which have the 
most benefit when commenced early during the course of illness.289 In the hospital and 
ICU settings, although viral detection may not alter antibiotic use due to concerns of 
secondary bacterial infection,244,255,290 rapidly detecting a bacterial pathogen such as 
B. pertussis would aid a clinician’s decision to prescribe and/or continue particular 
antibiotics.255 In hospital settings, rapid diagnosis of pertussis or another infectious 
respiratory pathogen would also accelerate the implementation of appropriate infection 
control measures, limiting the likelihood of nosocomial infections.244,257 Furthermore, when 
a diagnosis is obtained quickly, additional (often unnecessary) laboratory tests and 
diagnostic imaging (such as chest x-rays) may be avoided, therefore reducing healthcare 
costs.244,256,257  
Public Health 
From a public health perspective, the shift to PCR-based diagnosis has several important 
implications. With increasingly reliable diagnostic testing across all age groups, the less 
accurate notification of cases based on clinical symptoms alone will largely have been 
eliminated.38,175,273 The reliance on notification of laboratory-confirmed results has 
improved both the accuracy of pertussis surveillance and the understanding of pertussis 
epidemiology through the identification of cases that may have previously been 
undiagnosed.177 Although diagnostic testing increased across all ages, increases in 
pertussis incidence within particular age groups prompted the investigation and 
subsequent recognition of rapidly waning immunity associated with acellular pertussis 
vaccines, as well as the impact of removing the 18 month booster dose. These issues 
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have had direct impact on Australia’s immunisation policies and programs. For example, in 
response to mounting evidence of rapidly waning immunity, the 18 month booster was 
reinstated on the National Immunisation Schedule in 2015.291 The effect of this, and any 
future changes to the schedule, will be able to be monitored using population-based 
notification and other routinely collected data.  
However, an increase in underlying testing patterns can lead to misinterpretation of 
notification data, as was demonstrated with pertussis seasonality in Chapter 7. This is not 
only an issue for pertussis epidemiology, but also the epidemiology of all notifiable 
diseases and other important infectious diseases in Australia and other countries with 
similar laboratory-based surveillance systems. There is now a broad range of pathogens of 
public health concern, including vaccine preventable, sexually transmissible, and 
foodborne diseases, as well as antibiotic-resistant organisms, for which sensitive and 
specific laboratory diagnosis has become increasingly available.292 As demonstrated 
during the pertussis resurgence, increased testing leads to increased case finding and a 
magnification of notifications. A similar phenomenon has also been demonstrated for 
Chlamydia trachomatis notifications in Australia and overseas.293-296 This highlights the 
importance of understanding the underlying testing patterns when interpreting notification 
data or incidence rates, particularly when that interpretation will be used for public health 
funding, policy, or program decisions. Possible ways to resolve this issue are to either 
report total tests conducted per time period, to notify both positive and negative results, or 
to report the proportion of tests positive (using total tests as the denominator). To improve 
the interpretation of C. trachomatis notifications, as well as those for other sexually 
transmissible infections (STIs) and blood borne viruses (BBVs), the Australian 
Collaboration for Coordinated Enhanced Surveillance of STIs and BBVs (ACCESS) was 
developed.296,297 ACCESS is a sentinel surveillance system with the aim to describe 
characteristics and trends in C. trachomatis testing.298 Not only does this system capture 
testing trends, it can also describe testing frequency and outcomes, as well as the 
demographics of individuals undergoing testing.298 A more simplistic alternative was 
demonstrated by NSW Health, who collected and analysed laboratory testing denominator 
data (total tests conducted each month) for 10 notifiable diseases, including pertussis and 
C. trachomatis, between 2012 and 2014.299 National implementation of either approach, at 
least for the more common notifiable diseases, would greatly improve the interpretation of 
trends within notification data. It would also enhance the understanding of the 
epidemiology of notifiable diseases and support policy and program evaluation.  
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Future research 
A major limitation to monitoring and evaluating immunisation programs in Australia is the 
absence of a whole-of-life immunisation register. Currently, the Australian Childhood 
Immunisation Register (ACIR) only captures vaccination details for children up to seven 
years of age.300 This makes assessing the coverage of the adolescent booster dose and, 
more recently, cocoon and maternal vaccination program uptake very difficult.235,301 In 
2015, it was announced that the ACIR would be gradually expanded to become a 
whole-of-life immunisation register.151 Following implementation it should be possible to 
quantify national adolescent and adult immunisation coverage using this register, and 
formally evaluate immunisation programs in the target groups, including pregnant 
women.130 Additionally, the register will make it possible to better understand the 
epidemiology of pertussis by investigating the incidence and vaccine-effectiveness among 
adolescents, adults, and the elderly. Another exciting possibility is the linkage of 
notification, immunisation, laboratory, and hospital datasets. Possible investigations could 
include auditing the accuracy of notifications and/or hospital discharge coding,248,278 as 
well as assessing vaccine safety or vaccine-related adverse events.132  
The introduction, or re-introduction, of additional pertussis-containing vaccine doses or 
novel pertussis-containing vaccines requires enhanced surveillance of vaccine safety and 
adverse events to ensure the ability to identify and respond to any safety concerns 
appropriately, as well as to maintain public acceptance.302 Prior to its removal from the 
schedule, the 18 month booster dose was associated with increased risk of local reactions, 
including extensive limb swelling.269 As part of the re-introduction of the 18 month booster 
dose, the Australian Advisory Committee on the Safety of Vaccines recommended 
enhanced surveillance of adverse events following this dose, including active surveillance 
for a minimum of three years across all states and territories.303 Monitoring safety data 
from an active surveillance program in real time will provide vital information to inform 
decisions about continuing or moving the 18 month booster dose in the future.  
The contribution of Bordetella species, other than B. pertussis, to reported pertussis 
incidence is another area of important future research. Bordetella species have limited 
genetic diversity, and as such, commercially used PCR assays are often unable to 
differentiate between Bordetella species.13,20,179,181,183,184 Furthermore, immunisation 
against B. pertussis offers little protection against B. holmesii and B. parapertussis, and 
clinically, infection caused by these species can closely resembles B. pertussis infection.20 
Both B. holmesii and B. parapertussis have been detected in B. pertussis outbreaks and 
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are believed to contribute to pertussis notifications.13-20,103,183 In 2013, only 7% of 
Australian laboratories reported using multi-target PCR assays that could distinguish 
between the Bordetella species, with the remaining 93% of Australian laboratories likely to 
return false positive results for B. pertussis in approximately 90% of cases.13 As PCR 
assays are further improved and specialised to detect other species of Bordetella, such as 
B. holmesii and B. parapertussis, it may be possible to quantify the contribution of these 
species to pertussis notifications and assessments of vaccine effectiveness.13,179,181,183,184 
Improved understanding of the epidemiology and prevalence of other Bordetella species 
may have implications for Australian immunisation policy and programs, as well as 
surveillance systems, for example through changes to case definitions or the list of 
notifiable diseases.  
Conclusions 
Overall, this Thesis has made an important, original contribution to understanding the 
resurgence of pertussis in Australia and overseas by addressing gaps in knowledge about 
changes in diagnostic testing. This work highlights the importance of understanding the 
underlying testing patterns when interpreting epidemiological or surveillance data, such as 
notifications. In summary, although a true increase in pertussis incidence occurred in 
Australia, increasing PCR-based diagnosis allowed better case detection across all age 
groups and healthcare settings. Greater understanding of pertussis epidemiology as a 
result of PCR diagnosis should ultimately improve pertussis immunisation and control 
programs, through better identification of at-risk groups.  
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Appendix 1: Bettering Evaluation and Care of Health (BEACH) methods 
(Supplementary material for Chapter 3) 
The BEACH program is a continuous cross-sectional national study collecting details of 
Australian general practice encounters that began in April 1998. Every year approximately 
1,000 randomly selected general practitioners (GPs) record details of 100 consecutive 
encounters on structured paper recording forms. Fields collected include problems 
managed, tests ordered and treatments prescribed. Data about the patients, the doctors 
and their practices are also recorded with collection evenly distributed throughout 50 
weeks of each year. GPs are randomly selected quarterly, with those who claimed at least 
375 general practice Medicare items of service in the previous quarter eligible to 
participate.1  
Each year the proportion of contactable GPs who agree to participate in the BEACH 
survey is approximately 30%. The age and sex distribution of patients at encounters 
included in the BEACH study has repeatedly been shown to accurately represent all GP 
service encounters for which Medicare claims have been made.219  Problems managed 
and tests ordered are recorded in the free text by the GPs and are secondarily coded 
using ICPC-2 Plus (Australian general practice interface terminology classified according 
to the International Classification of Primary Care – Version 2).2   
 
1.  Britt H, Miller G, Charles J, Henderson J, Bayram C, Valenti L, Harrison CM, Pan Y, O’Halloran J, 
Zhang C, Fahridin S. General Practice Series no.29: General practice activity in Australia 2010–11. 
Sydney: Sydney University Press, 2011. Available from: http://www.aihw.gov.au/publication-
detail/?id=6442472433 [Accessed Jun 2016] 
 
2.  Wonca International Classification Committee. ICPC–2 English: International Classification of Primary 
Care - 2nd Edition. Singapore: World Organization of Family Doctors, 1998. Available from: 
http://www.kith.no/upload/2705/ICPC-2-English.pdf [Accessed Jun 2016] 
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Appendix 2: Bettering the Evaluation and Care of Health (BEACH) problems* chosen for inclusion in the pertussis-related 
problem (PRP) case definition, April 2009 to March 2011 (Supplementary material for Chapter 3) 
ICPC-2  
problem  
code* 
Corresponding problem label 
Percent of all pertussis tests ordered  
within encounters with this code  
% (n) 
Percent of GP management 
occasions of this problem at 
which a pertussis test ordered 
% 
R05 Cough 29.0% (110) 8.8% 
R71 Whooping Cough 24.0% (91) 37.1% 
R74 Upper respiratory infection, acute 12.9% (49) 0.5% 
R78 Acute bronchitis/bronchiolitis 11.8% (45) 1.0% 
R83 Respiratory infection, other 4.0% (15) 1.5% 
R96 Asthma 3.4% (13) 0.3% 
R81 Pneumonia 2.4% (9) 1.3% 
A23 Risk factor NOS 2.1% (8) 0.8% 
A33 Microbiology/immunology test NOS# 1.3% (5) 0.8% 
R27 Fear of respiratory disease, other 0.5% (2) 50.0% 
R33 Respiratory  - Microbiology/immunology test 0.3% (1) 20.0% 
R03 Wheezing 0.3% (1) 1.4% 
R09 Sinus symptom/complaint (including pain) 0.3% (1) 1.2% 
* BEACH use the International Classification of Primary Care – Version 2 (ICPC-2)304 to classify data, including the problems managed at encounters 
# NOS = Not otherwise specified 
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Appendix 3: Australian case definition for notifications of pertussis captured by the 
National Notifiable Diseases Surveillance System* (Supplementary material for 
Chapter 3) 
 A confirmed case requires:  
• Laboratory definitive evidence; OR 
• Laboratory suggestive evidence AND Clinical evidence; OR 
• Clinical evidence AND Epidemiological evidence. 
 
Laboratory 
definitive evidence: 
Laboratory suggestive 
evidence: 
Clinical 
evidence: 
Epidemiological evidence: 
Isolation of Bordetella 
pertussis or detection 
of B. pertussis by 
nucleic acid testing 
Seroconversion or 
significant increase in 
antibody level or fourfold or 
greater rise in titre to B. 
pertussis in the absence of 
recent pertussis 
vaccination, or single high 
IgA titre to whole cells, or 
detection of B. pertussis 
antigen by 
immunofluorescence 
assay (IFA) 
A coughing illness 
lasting two or 
more weeks, or 
paroxysms of 
coughing or 
inspiratory whoop 
or post-tussive 
vomiting 
Contact between two people 
involving plausible mode of 
transmission at a time when: one 
of them is likely to be infectious, 
and the other has an illness 
which starts within 6-20 days 
after this contact, and at least 
one case in the chain of 
epidemiologically linked cases is 
a confirmed case with at least 
laboratory suggestive evidence 
 
* Australian Government Department of Health. Australian national notifiable diseases case definitions: 
Pertussis case definition. 2014. Available from: 
http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_pertus.htm 
[Accessed Jun 2016]. 
